

# TSETSE AND TRYPANOSOMIASIS INFORMATION QUARTERLY

**Index**

**Volume 20**

**Part 1–4, 1997**

**Numbers 9783–10254**



**DFID**



Cirad-emvt

## **Africa**

### Central

- trypanosomiasis control, 9783
- trypanosomiasis in humans

model, 9887

Niari focus, 9887

- treatment, 9929

- tsetse control, 9783

### East

- G. pallidipes*, gene diversity and gene flow, 10027

- trypanosomiasis in humans, *rhodesiense*, 9807

### French Equatorial Africa

- trypanosomiasis in humans

history of screening, 9890

- vector control, history, 9890

### southern

- common fly belt

mapping tsetse habitat suitability, 10155

tsetse distribution, 10154

- G. pallidipes*, gene diversity and gene flow, 10027

- tsetse control

ecological side effects, 10036

### sub-Saharan

- tsetse control, 9788

tsetse distribution studies

- effect of global warming, 10034

- multivariate analysis of climate and vegetation, 10155

- NDVI analysis, 10154

- univariate analysis of habitat, 10154

### West

- livestock development potential, 9786

- T. brucei* stocks, genotype, 10099

- T. vivax*, diagnosis, 10073

- trypanosomiasis in humans

- treatment, 9929

- trypanosomiasis in livestock, 9786

- trypanotolerance in livestock, 9785

- tsetse control, 9786

ecological side effects, 10036

## **antibodies**

*see also* immune response

- anti-peptide, against trypanopain-Tb, 10248

- auto-antibodies

to neurofilament proteins, 10164

to DNA and collagen, 10077

- endotoxin antibodies in human trypano-somiasis, 10045

- maternal transmission, cattle, 9827

- monoclonal

- in diagnostic testing, 9935, 10073, 10175, 10178

- native VSG-specific, in cattle, humans and mice, 9840

- polyclonal

- in diagnostic testing, 10073

- response to invariant antigens, modelling, 10055

- seroprevalence, cattle, Kenya, 10015

## **antigenic variation**

- in trypanosomes, 10209

- and problem of vaccines, 10001

*T. brucei*, 9978, 9995, 10211, 10250

*T. congolense*

interaction with host immune system

modelling, 10055

### **antigens**

*see also* variant surface glycoprotein

trypanosome

autoantigen I/6, 10105

crude, extraction for diagnosis, 10072

soluble, electrophoretic study, 10254

**attractants/attractiveness for tsetse** *see* odour attractants

### ***Bacillus thuringiensis***

gene cloning and expression, 9916, 9917

toxicity against *G. m. morsitans*, 9916, 9917

**baits** *see* odour attractants

### **barriers**

to reinvasion in tsetse-freed areas

targets, 9803

### **Benin**

*T. b. brucei* infection (exp.) in cattle, 10170, 10182

**Berenil** *see* diminazene aceturate

### **biting flies**

in Nigeria, 10052, 10054

### **blood**

cattle

haematology of *T. congolense* infection, 10056, 10057

trace element levels, role in trypano-tolerance, 10062

in pharmacokinetic studies, 10047

role in transformation of trypanosomes to procyclic forms, 9921

### **blood meals**

corresponding to biomass, 9938

identification in tsetse, 10037, 10038, 10039, 10041

methods, 10039

### **buffalo**

serum trypanocidal protein, 10196

### **Burkina Faso**

entomological survey, 9800, 9922

*G. p. gambiensis*, 9798, 9800, 9922

*G. tachinoides*, 9800, 9922

trypanosome isolates from domestic animals

molecular characterisation, 10179

trypanosomiasis in cattle, 9800

trypanosomiasis in donkeys, 9800

tsetse control

eradication campaign, 9800

trapping, 9800

### **camels**

*T. evansi* infection, 10184, 10187

diagnosis, 10175, 10177, 10178, 10181

in Kenya, 10175

pathology, 10181

treatment

Cymelarsan, 10190

melarsomine, 10187

*T. evansi* infection (exp.)

chemotherapeutic response, 10187, 10190  
effect on haemolytic complement activity, 10187  
trypanosomiasis  
concentration of serum micro- and macro-elements, 10061  
in Sudan, 10181

## Cameroon

trypanosome infections in pigs  
*T. brucei*, 9937  
*T. congolense*, 9937  
*T. simiae*, 9937  
*T. vivax*, 9937  
trypanosomiasis in humans, *gambiense*, 9810  
epidemiological surveillance, 10163  
Fontem focus, 9810, 9924  
history and evolution, 9897  
Mbam focus, 9810

## cattle

as host for tsetse, 9919, 10038  
Baoulé  
breed status, Côte d'Ivoire, 10144  
Boran  
Galana  
*T. vivax* infection (exp.)  
effect on ovarian activity, 9822  
effect on pregnancy, 9822  
trypanosusceptibility, 9822  
Orma  
*T. vivax* infection (exp.)  
effect on ovarian activity, 9822  
effect on pregnancy, 9822  
trypanotolerance, 9822  
*T. congolense* infection  
drug resistance, Ethiopia, 10071  
*T. congolense* infection (exp.), 10069  
haematology  
cytomorphological changes in blood and bone marrow, 10056  
macrophage structure and function in bone marrow, 10057  
immune response, 10056, 10057  
T-cell mediated, 9821  
infectivity and transmissibility of drug-resistant strains, 10188  
pharmacokinetics of isometamidium, 9830  
serum concentration of isometamidium, 10069  
trypanosusceptibility, 9821  
Borgou  
detection of blood antigens, 10170  
*T. b. brucei* infection (exp.), 10182  
trypanotolerance, 10182  
bovine analogues of human trypanolytic factors, 10066  
breed composition and relationships, investigation, 10065  
Bunaji  
productivity, Nigeria, 10067  
crosses  
N'Dama  $\exists$  Boran  
genetic mapping of trypano-susceptibility, 10063  
N'Dama  $\exists$  Gobra  
*T. congolense* infection (exp.), 9936  
Drakensberger

- genetic studies, 10064
- Fogera
  - genetic studies, 10064
- Friesian
  - genetic studies, 10064
  - treatment, drug, 9819
  - T. brucei* infection, 10172
  - T. congolense* infection, 10172
  - T. vivax* infection, 9819, 10172
  - trypanosomiasis prevalence, Nigeria, 10172
- genetic diversity and breed relationships
  - microsatellite analysis, 10064
- Gobra
  - T. congolense* infection (exp.), 9936
- Keteku
  - trypanotolerance
    - role of trace elements, 10062
- Lagune
  - breed status, Côte d'Ivoire, 10144
  - detection of blood antigens, 10170
  - T. b. brucei* infection (exp.), 10182
  - trypanotolerance, 10182
- Muturu
  - genetic studies, 10064
  - productivity, Nigeria, 10067
- T. brucei* infection, 10172, 10173
- T. congolense* infection, 10172, 10173
- T. vivax* infection, 10172, 10173
- trypanosomiasis prevalence, Nigeria, 10172, 10173
  - native VSG-specific antibodies, 9840
- N'Dama
  - breed status, Côte d'Ivoire, 10144
  - genetic studies, 10064
  - in Gambia, 9938
  - parasitaemia profiles, 10055
  - T. brucei* infection, 10172, 10173
  - T. congolense* infection, 10172, 10173
  - T. congolense* infection (exp.), 9936
- antibody response to invariant antigens, 10055
  - immune response
    - modelling, 10055
    - T-cell mediated, 9821
  - T. vivax* infection, 10172, 10173
- trypanosome infection, Gambia, 9938
- trypanosomiasis prevalence, Nigeria, 10172, 10173
  - trypanotolerance, 9821
- pharmacokinetics
  - isometamidium chloride, 9944
- serum, drug concentrations in, 9829, 10069, 10070
- treatment
  - chemoprophylaxis
    - isometamidium chloride, 9829
    - drug accumulation, 10189
    - weight loss, 10189
  - combination, isometamidium and diminazene
    - hepatic damage, 10189
    - mortality, 10189

- weight loss, 10189
- diminazene aceturate, 9802
- insecticide
  - deltamethrin, 9800
  - pour-on, 9784, 9793
- resistance
  - T. congolense*, Nigeria, 10191
  - T. vivax*, Nigeria, 10191
- sustained release devices
  - homidium, 10070
  - isometamidium, 10070
- T. brucei* infection, 9932, 9935, 10053
- T. brucei* stocks from, Uganda, 10206
- T. b. brucei* stocks from, East Africa, 9807
- T. congolense* infection, 9932, 9934, 9935, 10037, 10052, 10053
- T. congolense* infection (exp.)
  - haematological effects, 10056, 10057
  - immune response, 9825
    - macrophage structure and function, 10057
  - infectivity and transmissibility of drug-resistant strains to tsetse, drug treatment effects, 10188
- T. evansi* infection (exp.)
  - trypanocide testing, 10096
- T. vivax* infection, 9932, 9935, 10037, 10052
  - isolates from West Africa, Kenya, South America, diagnosis, 10073
- T. vivax* infection (exp.), 10051
  - immune response, 9825
- trypanosome prevalence
  - in Ethiopia, 9932
  - in Nigeria, 10174
- trypanosomiasis
  - diagnosis, 9932, 9935, 10051, 10053, 10073, 10171
  - in Burkina Faso, 9800
  - in Ethiopia, 9802, 9932
  - in Gambia, 9938
  - in Ghana, 9935
  - in Nigeria, 9934, 10052
  - in sub-Saharan Africa, 9788
  - in Zambia, 10053
  - mixed trypanosome infection, 9800, 9935
  - serological status
    - impact of biological factors on interpretation, 10171
  - T. brucei* infection, 9800, 10053, 10173
  - T. congolense* infection, 9800, 9802, 9934, 10052, 10053, 10173
  - T. vivax* infection, 9800, 10052, 10173, 10174
- trypanosusceptibility
  - genetics, 10063
  - phenotype and microsatellite allele frequency data, 10065

**cattle (cont.)**

- trypanotolerance, 9786, 9793, 10182
  - bovine analogues of human trypanolytic factors, 10066
  - genetics, 10063, 10066
  - phenotype and microsatellite allele frequency data, 10065
  - role of trace elements, 10062
- trypanotolerant

- T. congolense* infection
  - maternal transmission of antibody, 9827
- tsetse challenge to, Gambia, 9938
- White Bororo
  - detection of blood antigens, 10170
- White Fulani
  - trace element levels, 10062
  - T. congolense* infection, Nigeria, 9934
- Zebu
  - Highland, genetic studies, 10064
  - T. brucei* infection, 10172, 10173
  - T. congolense* infection, 10172, 10173
  - T. vivax* infection, 10172, 10173
  - trypanosomiasis
    - prevalence, Nigeria, 10172, 10173
    - treatment, side effects, 10189
  - trypanosusceptibility, 9786

### **Central African Republic**

- G. f. fuscipes*, 9801, 9806
- trypanosomiasis in humans
  - epidemiological surveillance, 10163
  - history and evolution, 9888
- tsetse control, 9806
- trapping, 9801

### **central nervous system (CNS)**

- in trypanosomiasis
  - in humans, 9811, 9812
- model, mice, 10078
- neurofilament proteins in, 10164
- trypanosomes in, 9814
  - in mice
    - RP-67,580 effect, 10079

### **cerebrospinal fluid (CSF)**

- in human trypanosomiasis, 9811
  - auto-antibodies in, 10164
  - cell count, 9817, 9930
  - DFMO in, 9816, 10049
  - melarsoprol in, 9813, 10047
  - protein in, 9930
  - trypanosomes in, 9817, 9930
  - white blood cells in, 9930

### **Chad**

- trypanosomiasis in humans
  - epidemiological surveillance, 10163
  - history and evolution, 9889

### **challenge**

- tsetse
  - to cattle
    - in Gambia, 9938
    - in Zimbabwe, 9829
  - to equines, Gambia, 9938
  - to goats, Zambia, 9939
  - to small ruminants, Gambia, 9938

### **characterisation**

- see also* identification/detection
  - of trypanosomes
    - by hybridisation, 9918

- by isoenzyme electrophoresis, 9976, 10099, 10180, 10206
- by PCR, 9918, 9922, 10179
- molecular, 9918, 10179

**chemoprophylaxis**

- in cattle, 9829
  - hepatic damage, 10189
- in goats, 9939
- in horses, 10059
- sustained release devices, 10070, 10089

**chemosterilants**

- on tsetse traps, 9793

**chemotherapeutics**

- sterol metabolism, potential for chemo-therapeutic exploitation, 9982

**chemotherapy**

- causing reduced transmissibility/infectivity of drug-resistant *T. congolense*, 10188
- combination, causing hepatic damage in cattle, 10189
- in *T. congolense*-infected goats, 10068
  - effect on haematological and serum biochemical parameters, 10068
- of trypanosomiasis
  - in goats, 9939
  - in horses, 10059
  - in humans, 9929, 9931
  - toxicity, 9931

**Congo (People's Republic)**

- trypanosomiasis in humans
  - epidemiological surveillance, 10163
  - history and evolution, 9898
- tsetse trapping campaign, 9784

**control, trypanosomiasis**

- case-finding surveys
  - low participation rate, 10043
- community participation, 9800, 9896
- cost, 9785, 9791, 9793, 9800
- cost-effectiveness, 9793
- detection of infected individuals, 10014
- drug use, 10016
- fear of drug-induced mortality, 10043
- historical aspects, 9888, 9889, 9890, 9891, 9897, 9898, 9899, 9900
- in Africa
  - Central, 9783
  - sub-Saharan, 9788
- in Burkina Faso, 9800
- in Ethiopia, 9802
- in tsetse-free zones, 9932, 9933
- in Zaire, 9785
- integrated, 9793, 10140
- modelling, 9783, 9887, 9892, 10014, 10015
- review, 10016
- strategies, 9783, 9914, 9972, 10014, 10016, 10138
- sustainability, 9914, 10140
- treatment, 10014
- trypanotolerant livestock, 9793
- vaccine research, problems, 10001
- vector control, 9783, 9784, 9786, 9788, 9790, 9800, 9802, 9890, 9895, 10014, 10016, 10174



## control, tsetse

biological, potential

*Bacillus thuringiensis*, 9916, 9917

*Metarhizium anisopliae*, 10035

bush clearance, 9786, 9790

chemosterilants, 9793

community participation, 9800, 9896, 9901, 9915, 10019, 10139

control herds, 9791

cost, 9791, 9793, 9800, 9914

ecological implications, 10018

eradication, 9800

growth regulators, 9793

historical aspects, 9890

impact

on bird species richness, 10021

on environment, 10021, 10036

on land use, 10036, 10143

on non-target species, 10018, 10036

on tree species composition, 10143

in Africa

Central, 9783

sub-Saharan, 9788

West, 9786

in Burkina Faso, 9800

in Congo, 9784

in Côte d'Ivoire, 9784, 9791, 10036

in Ethiopia, 9791, 9802, 10021

in Kenya, 9789, 10019, 10139

in Tanzania, 9790, 9896, 9915

in Uganda, 9784

in Zimbabwe, 9799, 9914, 10156

insecticide

cattle treatment, 9800, 9914

pour-on, 9784, 9793

cypermethrin, 9901, 9915

DDT, 9914

deltamethrin, 9800, 9802, 10036

endosulfan, 10036

impregnated traps/targets/screens, 9914

spraying

aerial, 9914, 10036

ground, 9914, 10036

integrated pest management, 10019, 10020, 10140

land use associations, 10018

models/modelling, 9791, 9892

odour attractants, 10156

questionnaire, 9896

rural development associations, 10018, 10140

screens, 9784, 9793

socio-economic planning, 9788

socio-economics, 10020

sterile insect technique, 9793

strategies, 9887, 9892, 9914, 10138

sustainability, 9895, 9914, 10140

targets, 9802, 9901, 9914

insecticide-treated, 9914, 9915, 10036

- odour-baited, 10036
- training, 10019
- traps/trapping, 9784, 9789, 9793, 9799, 9800, 9801, 9892, 9901

### **Côte d'Ivoire**

- blood meal identification, 10039
- cattle, status, 10144
- domestic animals, breed status, 10144
- G. nigrofuscus*, 10030, 10151
- G. pallicera*, 10030, 10151
- G. palpalis*, 10030, 10039, 10151
- goats, status, 10144
- pigs, status, 10144
- plants, trypanocidal activity, 9968
- poultry, status, 10144
- sheep, status, 10144
- T. brucei* s.l. populations from
  - characterisation, 10099
  - epidemiological considerations, 10099
  - taxonomical considerations, 10099
- trypanosome infections in tsetse, 10158
- trypanosome isolates from wild animals
  - epidemiological considerations, 10180
  - identification, 10180
- trypanosomiasis in humans, 9831
- transmission dynamics
  - role of human behaviour, 10157
  - trypanotolerant livestock, 10144
  - tsetse control
- trapping campaign, 9784, 9791

### **culture**

*see also in vitro* studies

- T. brucei* bloodstream form, 9852, 10097
- T. b. brucei*, 9975
- T. b. gambiense*, 9975
- T. congolense*, effect of cytokines, 10194
- T. evansi* bloodstream form, 10097
- T. vivax*, 9975

### **Cymelarsan**

- evaluation, in *T. evansi*-infected camels, 10190
- resistance, in *T. brucei*, 10204
- treatment of trypanosomiasis in camels, 10190

### **cypermethrin**

- impregnated
  - targets, 9915
  - traps, 9800

### **DDT**

- in tsetse control
  - Zimbabwe, 9804, 9914
- residues, 9804

### **deltamethrin**

- cattle treatment, 9800
- impregnated targets, 9802
- in tsetse control
  - environmental impact, 10036
  - Zimbabwe, 9804

**detection**

*see also* characterisation/identification  
of infected individuals, 10014  
of *T. vivax* using single DNA probe, 10073  
of trypanosomes  
by bDNA-based assay, 9831  
by mouse infectivity, 9809  
by PCR, amplification, 9809, 9810  
comparison of techniques, 9809, 9810  
in blood, 9925, 9926  
in tsetse saliva, 9809  
in tsetse midgut, 9925, 9926

**DFMO** *see* difluoromethylornithine

**diagnosis**

comparison of techniques, 9810, 9935, 9936, 10051, 10053, 10170, 10173, 10175  
difficulty, 9895, 10078  
evaluation of techniques, 9924, 9935, 9937, 10072, 10169, 10177  
of animal trypanosomiasis, 9925, 9932, 9935, 10051, 10053, 10054, 10168, 10169  
of human trypanosomiasis, 9831, 9925  
parasitological, 9785, 9810, 9811, 9812, 10054, 10180  
serological, 9785, 9810, 9811, 9924, 10044, 10072, 10180

**diagnostic techniques**

anion-exchange centrifugation technique, 9945  
mini-anion exchange, 9810  
bDNA-based assay, 9831  
blood smear, 10180  
buffy coat examination, 9808, 9831, 9932, 9935, 9936, 10051, 10053, 10054, 10073, 10169, 10170  
  
CATT, 9810, 9924, 10044, 10177, 10180  
  micro-, 10163  
  on whole blood, 9924  
DNA probes, 10073  
double immunodiffusion test (DID), 10177  
ELISA  
  Ab-, 10072, 10168, 10171  
  Ag-, 9935, 9936, 10051, 10168, 10170, 10175, 10177, 10180  
  dot-, 10192  
haematocrit centrifugation technique, 9810, 10051  
  microhaematocrit, 10053  
indirect immunofluorescence, 10044  
KIVI, 9810, 10180  
latex agglutination, 9935, 10072  
lymph gland aspiration, 9810  
mercuric chloride, 10177  
mouse infectivity, 9809  
mouse inoculation, 10177  
PCR, 9809, 9810, 9925, 9926, 9937, 10051, 10073, 10169, 10179  
  on filter paper, 10053  
rat inoculation, 9811  
thick blood film, 9810, 9812, 10177  
thin blood smear, 10053  
wet blood film, 10169, 10177

**difluoromethylornithine (DFMO, eflornithine)**

pharmacokinetics

in humans, 10049  
in *T. b. brucei*-infected mice, 10090  
role in neuropathogenesis, mice, 10201  
treatment

of *T. brucei*-infected rats  
combined with isometamidium, 9967  
of *T. congolense*-infected rats, 10085  
combined with levamisole, 10085  
of trypanosomiasis  
in humans, 9784, 9929, 10044  
combined with suramin, 9817  
*gambiense*, 9816  
relapse, 9816, 10167  
*rhodesiense*, 9817  
treatment failure, 10167

**diminazene aceturate**, 9872, 9873

causing paralysis in mice, 10084  
effect on infectivity and transmissibility of drug-resistant *T. congolense* in *G. m. centralis*, 10188  
mode of action, 10048  
residues in animals and foods, 10013, 10023, 10024  
resistance  
in *T. brucei* stocks from man and domestic animals, Uganda, 9972  
in *T. congolense*, 10071, 10188, 10191, 10203  
in *T. vivax*, 9819, 10191  
sensitisation study, guinea pigs, 9966  
toxicity, 10189  
treatment  
of *T. congolense* infection in goats, 10060, 10068  
of *T. evansi* infection in goats, 9823  
of *T. vivax* infection in horses, 10059  
of trypanosomiasis in cattle  
relapse, 9802  
of trypanosomiasis in goats, 9939

**DNA**

amplification by PCR, 10073  
auto-antibodies to, in *T. equiperdum* infection, 10077  
branched, assay  
for detection of *T. brucei* in human blood, 9831  
content in *T. brucei* ssp., wide variation, 10119  
human, for PCR analysis, 9810  
oligonucleotide primers, 10073  
probes  
for trypanosome identification, 9806, 10073  
*T. grayi*, 9806  
trypanosome  
amplification for detection  
*T. vivax*, 10073  
kinetoplast, minicircles  
inheritance in genetic crosses, 10221  
kinetoplast, replication, 9880  
electrophoretic comparison, 10137  
*T. brucei*, 9831  
virus, in *G. m. centralis*, 10147

**dogs**

*T. brucei* stocks from, Uganda, 10206  
*T. brucei* infection (exp.)

- immune response, 9826
- T. congolense* infection (exp.)
  - immune response, 9826
  - maternal transmission of antibodies, 9827

**domestic animals**

- status of breeds, Côte d'Ivoire, 10144
- T. brucei* isolates from, Uganda
  - drug sensitivity testing, 9972

**domestic ruminants**

- T. congolense* infections, 9940
- trypanosomiasis
  - effect on reproductive performance, 9940

**donkeys**

- T. congolense* infection, 9800
- trypanosome prevalence, Gambia, 9938
- trypanosomiasis, Burkina Faso, 9800
- tsetse challenge to, Gambia, 9938

**drug/s**

- combinations, 9929
  - DFMO and isometamidium, in rats, 9967
  - DFMO and levamisole, in rats, 10085
  - diminazene and isometamidium
    - sensitisation study, guinea pigs, 9966
  - isometamidium and diminazene
    - hepatic damage, 10189
    - weight loss, 10189
- melarsoprol and suramin, 10166
  - costs, 9895
  - design, 10100
  - development, 9848, 9927, 10017
- orphan drug status, 10017
  - mode of action, 10016, 10048
  - pharmacokinetics
    - DFMO, 10049, 10090
    - isometamidium chloride, 9830, 9944
    - melarsoprol, 10047, 10166
    - pentamidine, 9815
- prescribing information, 9818
- relapse rates, 9929
- residues in animal products, 9793
- residues in food, 10013, 10022, 10023, 10024
- resistance, 9793
  - Cymelarsan, 10204
  - diminazene aceturate, 9819, 9972, 10173, 10188, 10191, 10203
  - homidium, 10203
    - in *T. b. rhodesiense*, 9929
    - in *T. congolense*, 9802, 10069, 10071, 10188, 10191
    - in *T. vivax*, 10191
  - isometamidium, 9972, 10069, 10173, 10191, 10203
  - mechanisms, 9973
  - pentamidine, 9929
  - quinapyramine, 10203
- side effects
  - diminazene, 10189
  - isometamidium, 10189
  - melarsoprol, 9929
- sustained release devices

- homidium, 10070, 10089
- isometamidium, 10070, 10089
- preparation and evaluation, 10089
- targets, 9867, 9871, 9929
- tissue residues
  - isometamidium, 9830
- toxicity, 9785, 9793, 9895
  - evaluation of cytotoxicity, 10087
  - isometamidium and diminazene, 10189
  - melarsoprol, 9814
  - suramin, 9814
- trypanocidal, 9799, 9847
  - Cymelarsan, 10190, 10204

**drug/s (cont.)**

trypanocidal (cont.)

- DFMO, 9784, 9793, 9816, 9817, 9929, 10016, 10044, 10085, 10090, 10201
- diminazene, 9802, 9819, 9823, 9966, 10013, 10016, 10023, 10024, 10048, 10059, 10060, 10071, 10084, 10173, 10186, 10188, 10191
- ethidium *see* homidium
- fexinidazole, 9846
- homidium, 10016, 10070, 10071, 10203
- isometamidium, 9793, 9819, 9829, 9830, 9966, 10016, 10022, 10059, 10069, 10070, 10071, 10173, 10191
- levamisole, 10085
- melarsomine, 10187
- melarsoprol, 9811, 9813, 9814, 9816, 9846, 9927, 9929, 10016, 10044, 10048, 10204
- MelCy, 9793
- Mk-436, 9846
- nifurtimox, 9929
- nitroimidazoles, 9846, 9927
- pentamidine, 9811, 9815, 9927, 9929, 9930, 10016, 10048, 10050
- quinapyramine, 10175, 10203
- suramin, 9811, 9814, 9817, 9927, 9929, 10016, 10202
- T-46, 10205
- tryparsamide, 10016, 10048

**eflornithine** *see* difluoromethylornithine

**endosulfan**

tsetse control, environmental impact, 10036

**endosymbionts in tsetse**

P- (*Wigglesworthia glossinidia*), 10145

phylogeny, 10145

S- (Enterobacteriaceae), 10145

transmission routes, 10145

*Wolbachia pipientis*, 10145

**environment**

*see also* non-target organisms

- ecological side-effects of tsetse control, 10018, 10036

**epidemics**

- of human trypanosomiasis, 9787

- in East Africa, 9807

- in Uganda, 9918

- origins, 9784

- T. b. rhodesiense*, 9807

## **epidemiology**

epidemiological risk

index of, calculation, 10039

indicator, 10157

epidemiological surveillance

in OCEAC countries, 10163

in Côte d'Ivoire, 10157, 10180

in Uganda, 10206

in Zaire, 9785

models, 9892

of trypanosomiasis

in humans, 9787, 9918, 10157

revival of foci

causes, 9900

risk, 9888, 9891, 9897, 9900

in ruminants, Nigeria, 10173, 10174

risk of spread of human-infective *T. brucei* by rhinoceros

translocation, 9920

role of animal reservoir, 9784

unresolved problems, 9892

## **Equatorial Guinea**

trypanosomiasis in humans, *gambiense*

epidemiological surveillance, 10163

history and evolution, 9899

## **Ethiopia**

Ghibe Valley

*G. pallidipes*, 9802

model of vegetative change, 10143

trypanosomiasis in cattle, 9802

control, 9802

*T. congolense*, drug resistant isolates, chromosome profiles, 10071

*T. congolense*, multiple drug resistance, 10071

tsetse control, 9802

campaign, 9791

effect on bird species richness, 10021

effect on tree species composition, 10143

trapping, 9802

highlands (Arsi and Bale Provinces)

*T. equiperdum* prevalence in horses, 10168

livestock diseases, control, 10141

*T. evansi* infection (exp.) in camels

treatment, 10190

trypanosome infections in tsetse, 10158

trypanosomiasis in cattle, prevalence, 9932

## **fexinidazole**

treatment of *T. b. brucei*-infected mice

combined with melarsoprol, 9846

## **fly belt**

common, southern Africa, 10154, 10155

## **Gabon**

trypanosome infections in tsetse, 10158

trypanosomiasis in humans

epidemiological surveillance, 10163

history and evolution, 9891

in children, 10044

treatment, 10044

## **Gambia, The**

trypanosomiasis prevalence

in Djallonké sheep, 9938

in N'Dama cattle, 9938

in West African Dwarf goats, 9938

tsetse challenge

and grazing ranges, 9938

in relation to trypanosomiasis prevalence, 9938

to cattle, 9938

to equines, 9938

to small ruminants, 9938

## **gene/s**

*see also* RNA

in cattle

*BoLA-DRB3*, 10063

bovine analogue of *PONA*, 10066

in trypanosomes

encoding mitochondrial DEAD-box protein, 10237

for T lymphocyte triggering factor, 10251

gene-1, expression site-associated, 9857

PRP8-homologous, 10235

*rab*, 9990, 10109

rRNA, analysis, 10098

SLA RNA, 10004

spliced leader RNA, 10114

U6 snRNA, 10238

*vsg*, expression site switching, 10116, 10216

## **genetic/s**

of cattle breeds, 10064, 10065

of resistance

in livestock, 10081

in mice, 9951, 10074, 10081, 10195

of trypanosusceptibility

genetic mapping, 10063

of trypanotolerance

bovine analogues of human trypanolytic factors, 10066

markers, 9828

segregation analysis, mice, 10083

selection, marker-assisted, 9828

variation, 9828

trypanosome

chromosomes

large and mini, partitioning, 10108

size polymorphism, 10236

clonality, 9807

developmental regulation, mechanisms, 10229

diversity, 9976, 10206

DNA,  $\beta$ -D-glucosylated, 10110

kDNA, electrophoretic comparison, 10137

kDNA minicircles, inheritance, 10221

endonuclease, 10126

evolutionary, 9976

exchange, 9807

expression of toxic gene products, 10103

gene expression, 9857, 9923



- gene sequences, single copy, 10120
- genome
- research, 10236
- and evolution, 9986
  - segregation, mechanism, 10107
  - sequencing and mapping, 9987
- heterogeneity, 10180
- karyotype nomenclature, 10009
- markers, 9976
- minisatellite sequence, single locus
  - distinguishing between *T. brucei* isolates, 10102
- phylogeny, 10098
- population, 9807
- procyclin, regulation and expression, 10243
- RNA
  - editing, 9865, 9881, 10126, 10231
- g
- database, 10129
- model, 10226
- pre-m, chimaeric molecules, 9877
- specified uridylyate insertion into pre-m, 9865
- m
- expression regulation in insect forms of *T. brucei*, 10219
- histone levels, regulation, 9859
- polysomal procyclin, 9863
- precursor, 9865
- procyclin, 3'
  - untranslated region, 10219
  - r, pseudouridine residues, mapping, 10123
  - telomere/subtelomere duplex, ST-2, 10217
  - trans-splicing, 9996, 10235
  - U6 snRNA gene promoter, 10238
  - variability, 9784
- tsetse
  - gene diversity and gene flow, *G. pallidipes*, 10027
- hybrid sterility, *G. p. palpalis*  $\times$  *G. p. gambiensis*, 10146
  - in control, 9793
  - marker genes, *G. palpalis*, 10146
  - microsatellite markers in population studies, *G. p. gambiensis*, 10028
  - white eye colour mutant, *G. m. submorsitans*, 10025
- geographical information systems (GIS)**
  - in analysis of vegetation cover, 10143
  - in assessment of impact of tsetse control, 10143
  - in epidemiological surveillance, 10163
- Ghana**
  - T. brucei* infection, cattle and sheep, 9935
  - T. congolense* infection, cattle and sheep, 9935
  - T. vivax* infection, cattle, goats and sheep, 9935
- Glossina**
  - behaviour
  - flight response to odours, 10031
  - flying height, 10153
  - host location strategy, 9908, 9913
    - biology, 9892
      - ageing techniques
        - ovarian, 9798, 10158
        - wing fray, 10158
      - anticoagulants, 10029

- cuticular hydrocarbons, 10148
- endosymbionts
  - phylogeny, 10145
  - transmission routes, 10145
- lectins, 9784
- olfactory attractants, 9892
- phenoloxidase activity, 10159
- pupal period, 9798
- rearing, 9903
  - materials and methods, 9903
- refractoriness, 10159
- reproduction, 9798
- RLOs, 9784
- survival of *T. brucei*, 10241
- susceptibility, 10159
- T. brucei* infection, 10158
- T. congolense* infection, 10158
  - susceptibility, 10160
- T. vivax* infection, 10158
- trypanosome cycle, 9784
- trypanosome infection
  - dynamics, 10158
  - establishment, 9923
  - experimental
    - detection, 10073
    - maturation, 9923, 10159
    - rate, 9799, 10160
- viviparity, 9798
  - control, 9799, 9892
    - biological, potential, 9916, 9917, 10035
    - in Africa
      - Central, 9783
      - sub-Saharan, 9788
      - West, 9786
    - in Congo, 9784
    - in Côte d'Ivoire, 9784, 9791
    - in Ethiopia, 9791
    - in Kenya, 9789
    - in Tanzania, 9790
    - in Uganda, 9784
    - in Zimbabwe, 9914
  - methods for dispensing attractants, 10156
  - trapping, 9784, 9789
- ecology
  - distribution
    - analysis, in southern Africa, 10154
      - multivariate, 10155
      - univariate, 10154
    - effect of global warming, 10034
    - in Côte d'Ivoire, 10030
    - prediction, using temperature, 10154
    - spatio-temporal patterns, 10151
  - habitat
    - environmental variables, 10155
    - suitability, mapping, 10155
  - population/s
    - adult survival rate, 9798

- dynamics, 9798, 9909
- growth rate, 9798
- ovarian age structure, 9798
- pupal survival rate, 9798
- retreat, unfavourable climatic conditions, 9889
- sampling, 9901

genetics

- eye colour mutants, 10025
- gene diversity and gene flow, 10027
- hybrid sterility, 10146
- in control, 9793
- in population studies, 10028
- marker genes, 10146

***G. austeni***

- endosymbionts, S-, 10145
  - in Kenya, 10149
  - larvae, polypneustic lobes, 9797
  - response to odour, 10149
  - wing, chemoreceptors, 9795

***G. brevipalpis***

- endosymbionts, S-, 10145
  - in Kenya, 10149
  - larvae, polypneustic lobes, 9797
  - response to odour, 10149

***G. caliginea***

- cuticular hydrocarbons, 10148

***G. fuscipes***

- endosymbionts, S-, 10145
  - larvae, polypneustic lobes, 9797

***G. fuscipes fuscipes***

- blood meals, 9806
- control, trials, 9806
  - diel activity patterns, 10041
  - hosts, 9806
    - preferences, 10041
  - in Central African Republic, 9801, 9806
  - in Kenya, 10041
  - in Uganda, 10206
  - midgut infection, 9806
  - Nannomonas* infection, 9806
  - proboscis infection, 9806
  - salivary gland infection, 9806
  - trapping, 9801
    - efficiency of biconical trap, 10153
  - T. brucei* ssp. infection, 9806, 10206
  - T. grayi* infection, 9806
  - trypanosome infection, 9806

***G. fuscipes martinii***

- cuticular hydrocarbons, 10148

***G. longipalpis***

- cuticular hydrocarbons, 10148

***G. longipennis***

- distribution
  - movement between populations, 10150
- feeding, 9919
- feeding rate, 10037
- host preference, 9919

in Kenya, 9919, 10150  
larvae, polypneustic lobes, 9797  
transmission  
    *T. congolense*, 10037  
    *T. vivax*, 10037  
trapping pressure and population changes, 10150

***G. morsitans***

distribution  
effect of global warming, 10034  
larvae, polypneustic lobes, 9797  
parturition hormone, 9905  
*T. b. brucei* infection  
    regulation of parasite population, 10161  
trypanosome infection, 9805

***G. morsitans centralis***

biological control, technique  
    *Metarhizium anisopliae*, 10035  
cuticular hydrocarbons, 10148  
development of drug-resistant *T. congolense*, 10203  
distribution, southern Africa, 10154, 10155  
DNA virus infection (exp.), 9796  
    effect on feeding behaviour, 10147  
    effect on longevity, 10147  
    histological studies on midgut, 10147  
in Tanzania, 9901  
milk gland, 9796  
population sampling  
    flyround patrol techniques, 9910  
pregnancy cycle, 9796  
response to odour, 9911  
trapping, 9911, 9912  
*T. congolense* infection  
    drug-resistant, infectivity and transmissibility, 10188

***G. morsitans morsitans***

biological control, potential  
    *Bacillus thuringiensis*, 9916, 9917  
cibarium infection, 9808  
crop duct infection, 9808  
distribution, southern Africa, 10154, 10155  
DNA virus infection of salivary glands  
    effect on *T. brucei* infectivity and virulence, 10040  
endosymbionts, S-, 10145  
feeding preferences, 10038  
host location, 9913  
Malpighian tubules, temperature-induced changes in fluid secretion,  
9906  
midgut infection, 9808  
    role of host blood in transformation of trypanosomes to  
    procyclic forms, 9921  
oesophagus infection, 9808  
proboscis infection, 9808  
proventriculus infection, 9808  
response to odour, 9913  
trapping, 9803  
*T. brucei* infection  
    role of host blood in transformation to procyclic forms, 9921  
*T. b. rhodesiense* infection

susceptibility, 10159  
  *T. congolense* infection, 9805, 9808  
    in saliva, 9805  
    life cycle, 9808  
    maturation, 9805  
    susceptibility, 10160  
  vectorial competence, 9808, 10160  
  wing, chemoreceptors, 9795

***G. morsitans submorsitans***  
  cuticular hydrocarbons, 10148  
  in Gambia, 9938  
  in Nigeria, 10033, 10173  
  trapping, 10033  
  *T. congolense* infection  
    susceptibility, 10160  
  vectorial competence, 10160  
  white eye colour mutant, 10025  
  wing, chemoreceptors, 9795

***G. nigrofusca***  
  distribution and abundance  
    in Côte d'Ivoire, 10030, 10151  
  population dynamics, 10151

***G. pallicera***  
  distribution and abundance  
    in Côte d'Ivoire, 10030, 10151  
  population dynamics, 10151

***G. pallicera newsteadi***  
  cuticular hydrocarbons, 10148

***G. pallicera pallicera***  
  cuticular hydrocarbons, 10148

***G. pallidipes***  
  breeding structure, 10027  
  gene diversity and gene flow, 10027

control, insecticide, 9915

***G. pallidipes* (cont.)**  
  distribution  
    effect of global warming, 10034  
    in southern Africa, 10154, 10155  
    movement between populations, 10150  
  DNA virus infection, salivary gland, 9796  
  feeding  
    rate, 10037  
    response, 9799  
  flight  
    direction, 10031  
    video study, 10031  
  host location, 9908, 9911  
  in Ethiopia, 9802  
  in Kenya, 10149, 10150  
  in Tanzania, 9896, 9901, 9915  
  in Zimbabwe, 9799, 10031  
  larvae, polypneustic lobes, 9797  
  olfactory receptors  
    electrical response to host odours, 9907  
  population sampling  
    flyround patrol techniques, 9910  
    in Kenya, 9915, 10150

response to odour, 9799, 9907, 9908, 9911, 10031, 10149  
response to repellents, 9799  
salivary gland, hypertrophied, 9796  
transmission  
  cyclical, of trypanosomes, 9795  
  of *T. congolense*, 10037  
  of *T. vivax*, 10037  
trapping, 9799, 9802, 9803, 9911, 9912  
  pressure, and population changes, 10150  
wing, chemoreceptors, 9795

***G. palpalis***

distribution and abundance  
  in Côte d'Ivoire, 10030, 10151  
  in Nigeria, 10033  
insemination time, Côte d'Ivoire, 10026  
larvae, polypneustic lobes, 9797  
population dynamics, 10151

***G. palpalis gambiensis***

genetics  
  hybrid sterility, 10146  
  marker genes, 10146  
  population studies  
    microsatellite markers, 10028  
habitat, 9798  
  in Burkina Faso, 9798, 9800, 9922  
  in Gambia, 9938  
  in Senegal, 10059  
life span of female  
  effect on weight and size of progeny, 9904  
population dynamics, 9798  
trapping, 9800  
*T. congolense* infection, susceptibility, 10160  
*T. simiae* infection, 9922  
*T. vivax* infection, 9922  
vectorial competence, 10160

***G. palpalis palpalis***

blood meals, identification, 10039  
ecology, 10052  
endosymbionts, S-, 10145  
genetics  
  hybrid sterility, 10146  
  marker genes, 10146  
  in Nigeria, 10052, 10173  
  rearing, 9819  
*T. b. rhodesiense* infection

refractoriness, 10159  
*T. vivax* infection, 10052

***G. swynnertoni***

control, 9915  
cuticular hydrocarbons, 10148  
host location, 9911  
  in Kenya, 10149  
  in Tanzania, 9896, 9901, 9915  
population sampling  
  flyround patrol techniques, 9910  
response to odour, 9910, 9911, 10149  
trapping, 9911, 9912

## ***G. tachinoides***

- in Burkina Faso, 9800, 9922
- in Nigeria, 10033, 10173, 10174
- larvae, polypneustic lobes, 9797
- proboscis, 9809
- rearing, 9819
- trapping, 9800, 10033
- T. congolense* infection
  - in saliva, 9805, 9809
  - maturation, 9805
  - rates, 9809
  - susceptibility, 10160
- T. simiae* infection, 9922
- T. vivax* infection, 9922
- vectorial competence, 9809, 10160

## **goats**

- Borno White, 9933, 10054
- drug resistance studies, 10191
- Kigezi
  - susceptibility to *T. congolense* infection, 10060
- Mashona
  - T. congolense* infection (exp.), 10068
    - haematological parameters, 10068
    - serum biochemical parameters, 10068
- Mubende
  - susceptibility to *T. congolense* infection, 10060
- Red Sokoto, 9933, 10054, 10173
- Small East African
  - influence of diet supplementation
    - on resistance to *T. congolense* infection, 10183
    - on response to diminazene treatment, 10183
  - susceptibility to *T. congolense* infection, 10060
- treatment
  - chemoprophylactic
    - isometamidium, 9939
  - curative
    - diminazene, 9939, 10060, 10068
- T. congolense* infection, Nigeria, 10173
- T. evansi* infection (exp.)
  - immune response, 9823
  - treatment, 9823
- T. vivax* infection
  - in Ghana, 9935
  - in Nigeria, 9933, 10054, 10173
- T. vivax* infection (exp.)
  - diagnosis, evaluation of PCR, 10169
  - drug sensitivity testing, 9819
- trypanosome prevalence, Nigeria, 10054
- trypanosomiasis prevalence, Nigeria, 10054, 10174
- trypanosomiasis, Zambia, 9939
  - effect on health and productivity, 9939
  - protective immunity, 9939
  - seasonal prevalence, 9939
  - susceptibility, effect of age, 9939
- trypanotolerance, 9786
- tsetse challenge to, 9939
- West African Dwarf, 10173

breed status, Côte d'Ivoire, 10144  
*T. vivax* infection (exp.)  
    effect of previous growth retardation  
        on energy, 10058  
        on nitrogen metabolism, 10058  
    effect on body temperature and posture, 9820  
trypanosome prevalence, 9938  
tsetse challenge to, 9938

#### **growth regulators**

on tsetse traps, 9793

#### **guinea pigs in laboratory studies**

sensitisation in combined drug treatment, 9966  
serum trypanocidal effect, 9955, 10197

#### **high density lipoproteins (HDL)**

in human serum  
trypanolytic role, 9841  
trypanosome resistance to, mechanism, 9991

#### **hippopotamus**

as host for *G. longipennis*, 9919

#### **homidium bromide/chloride**, 10016

in sustained release devices, 10070, 10089  
resistance in *T. congolense*, 10071, 10203

#### **horses**

*T. equiperdum* infection, Ethiopia, 10168  
*T. vivax* infection, Senegal, 10059  
trypanosomiasis  
    diagnosis, 10168  
    prevalence, Gambia, 9938  
    treatment, 10059  
tsetse challenge, 9938

#### **humans**

as host for tsetse, 10039, 10041  
native VSG-specific antibodies in, 9840  
*T. brucei* stocks from, Uganda, 10206

#### **identification**

*see also* characterisation/detection  
of trypanosomes  
    by DNA amplification using PCR, 9809  
    by DNA probes, 9806  
    by DNA sequencing, 9918  
    by hybridisation, 9806, 9918  
    by in situ hybridisation, 9918  
    by isoenzyme analysis, 10180  
    by PCR, 9809, 9918, 10179  
    by PCR-SHELA, 9918  
    by RFLP, 9918  
    by riboprinting, 9918  
    by touch-blot hybridisation, 9808  
species, 9918

*T. grayi*, 9806

#### **immune complexes**

in trypanosomiasis, 9842

#### **immune response**

in camels  
    haemolytic complement, 10187



- in cattle
  - antibody response
    - native VSG-specific, 9840
    - to invariant antigens, modelling, 10055
  - blood cell changes, 10056, 10057
  - bone marrow response, 10056, 10057
  - cell population changes
    - B-cells, 9821
    - lymph node cells, 9821
    - T-cells, 9825
      - CD2<sup>+</sup>, 9821
      - CD4<sup>+</sup>, 9821
      - CD8<sup>+</sup>, 9821
      - $\gamma\delta$ , 9821
- IFN- $\gamma$  production, 9821
  - lymphoblast proliferation, 10056
  - lymphocyte proliferation, 10056
  - macrophage proliferation, 10056
    - phagocytosis of blood cells, 10057
  - plasma cell proliferation, 10056
  - T-cell-mediated, 9821
- immune response** (cont.)
  - in dogs
  - antibody production, specific lytic, 9827
    - IFN- $\gamma$  production, 9826
  - in goats
    - antibody production, class-specific
      - IgG, 9823
      - IgM, 9823
    - reduced haemolytic complement, 9823
  - in humans, 9792, 9927
    - antibody production,
      - IgG, 10164
      - IgM, 9817, 10164
      - native VSG-specific, 9840
    - auto-antibodies
      - to neurofilament proteins, 10164
    - chancre, 9811
    - cytokines, 9928, 10046
    - IL-10, 10046
    - nitric oxide, 9928
    - prostaglandins, 9928
    - TNF- $\alpha$ , 10046
  - in mice, 9840
    - IFN- $\gamma$ , role in resistance, 9947
    - IFN- $\gamma$  stimulated proliferation of parasites, 9953
    - IL-4 production, 9834
  - native VSG-specific antibodies, 9840
    - suppressive mechanisms, macrophage-elicited, 9946
    - T-cell, 9833
  - in rabbits
  - auto-antibodies to DNA and collagen, 10077
  - in rats
    - immunomodulatory drugs, effect on *T. evansi* infection, 9954
    - leukocyte response, 10080
  - in sheep
    - haematological changes, peripheral, 9824

**immune system**

and parasites, 9957

**immunity**

development of protective immunity, goats, 9939

**immunodiagnosis**

production and use of crude antigens, 10072

**immunology**

of human trypanosomiasis, 9787, 9928

**immunosuppression**, 9823

in camels, 10187

in cattle, 9825

in mice, 9825, 9833

**insecticides**

cattle treatment

deltamethrin, 9800

pour-on, 9793, 9806

cypermethrin, 9800, 9915

residual effectiveness, 9915

DDT, 9804, 9912

deltamethrin, 9802, 10036

endosulfan, 10036

impregnated traps/screens/targets, 9793, 9800, 9802

**in vitro studies**

culture of *T. congolense*, effect of cytokines, 10194

growth of *T. b. brucei*, inhibition by ascofuranone, 9998

transformation of bloodstream *T. brucei* into procyclic forms, effect of host blood, 9921

with trypanosomes

*T. b. brucei* bloodstream form, 9870

**irradiation**

*T. evansi* infection (exp.) in mice

effect of  $\gamma$ -irradiation, 9950

**isometamidium chloride**

bioavailability in cattle, 9830

concentration in cattle sera, 9829, 10069

pharmacokinetics in cattle, 9830, 9944

prophylaxis

in horses, 10059

sustained release devices, 10070, 10089

residues

in cattle, 9830

in food, 10022

resistance

in *T. brucei* stocks from man and domestic animals, Uganda, 9972

in *T. congolense*, 10071, 10190, 10203

in *T. vivax*, 10191

sensitisation study, guinea pigs, 9966

sensitivity, in *T. vivax*, 9819

toxicity, 10189

treatment

combined with DFMO, in rats, 9967

in *T. vivax*-infected cattle, 9819

of trypanosomiasis in animals, 9793

of trypanosomiasis in goats, prophylactic, 9939

uptake kinetics, 10071

## Kenya

- Busia District
- survey, community participation potential, 10139
- Garissa District
- odour attractants, effects on tsetse catches, 10149
  - G. austeni*, 10149
  - G. brevipalpis*, 10149
  - G. f. fuscipes*, 10041
  - G. longipennis*, 9919, 10037, 10150
  - G. pallidipes*, 10027, 10037, 10149, 10150
- gene diversity and gene flow, 10027
  - G. swynnertoni*, 10149
- Lambwe Valley
  - community-based tsetse control, 10019
  - T. b. rhodesiense* transmission, 10042
  - tsetse trapping, 9789, 10019
  - Nannomonas* infecting rhinoceros, 9920
- Nguruman
- tsetse population changes, 10150
  - T. brucei* infecting rhinoceros, 9920
  - T. congolense* infecting rhinoceros, 9920
  - T. evansi* infecting camels, 10175, 10190
  - T. vivax*
    - diagnosis, 10073
    - infecting rhinoceros, 9920
  - trypanosome infections in tsetse, 10158
  - trypanosomiasis
    - in camels, 10175
    - in humans, *rhodesiense*, 9811
    - incidence in cattle, 10150

## land use

- change
  - associated with trypanosomiasis control, 10021
  - effect on bird species richness, 10021
  - effect on tree species composition, 10143
- impact of tsetse control, 10036
- planning
- role in tsetse control programmes, 9788

## livestock

- as host for tsetse, 10041
- development potential, West Africa, 9786
- resistance to trypanosomiasis, genetics, 10081
- status of breeds, Côte d'Ivoire, 10144
- trypanosomiasis, 9786
  - incidence, West Africa, 9786

## melarsomine

- treatment in *T. evansi*-infected camels, 10187

## melarsoprol

- effect on cytokine levels, 10046
- mode of action, 10048
- pharmacokinetics, 10047, 10166
- susceptibility testing, *T. brucei* stocks, Uganda, 9972
- topical gel
  - importance of 2,3-dimercaptopropinol in trypanocidal activity, 9969

toxicity, 9927, 10166

treatment

of human trypanosomiasis, 9890, 9929, 10044

*gambiense*, 9813, 9816

*rhodesiense*, 9811

toxicity, 9814

of *T. brucei*-infected mice, 10204

combined with other drugs, 9846

relapse, 10166

### **MelCy**

treatment of animal trypanosomiasis, 9793

### ***Metarhizium anisopliae***

biological control potential in tsetse, 10035

### **mice in laboratory studies**

genetics of trypanoresistance, 10074, 10081, 10195

native VSG-specific antibodies, 9840

*T. brucei* infection

immunosuppression, T-cell, 9833

suppressive mechanisms, macrophage-elicited, 9946

transformation, slender to stumpy forms, model, 10245

trypanocide testing, 9843

virulence, after development in DNA-virus infected tsetse, 10040

*T. b. brucei* infection, 9850

control of parasitaemia, 9834

drug effects, 9969

combination, 9846

effect on pharmacokinetics of DFMO, 10090

hind-leg paralysis, post-treatment, 10084

IFN- $\gamma$  stimulated proliferation of parasites, 9953

immune response, 9834

meningoencephalitic response, amelioration, 10079

model of human trypanosomiasis

neurological effects, 10078

role of DFMO in neuropathogenesis, 10201

trypanocide testing, 10088

trypanolytic activity of schistosomiasis-infected human plasma,  
9835

*T. b. gambiense* infection

role of DFMO in neuropathogenesis, 10201

trypanocide testing, 10088

*T. b. rhodesiense* infection

resistance, (IFN- $\gamma$ )-dependent, 9947

trypanocide testing, 10088

*T. congolense* infection, 10160

drug resistance studies, 10191, 10203

resistance, genetic control, 9951

trypanotolerance, case study, using segregation analysis, 10083

*T. evansi* infection

effect of dexamethasone, 9950

effect of  $\gamma$ -irradiation, 9950

trypanocide testing, 10096

### **mice in laboratory studies (cont.)**

*T. vivax* infection

drug resistance studies, 10191

trypanocide testing, 9958

trypanosome detection, 9809

## **MK-436**

treatment of *T. b. brucei*-infected mice  
combined with melarsoprol, 9846

### **models/modelling**

compartmental, human trypanosomiasis, 9887, 10014, 10138  
contingent valuation, community participation, 10139  
epidemiological models, development, 9892  
for gRNA from *T. brucei*, 10226  
logistic regression models  
impact of biological factors on bovine trypanosomiasis serology  
interpretation, 10171  
mathematical, *T. congolense* in cattle, 10055  
matrix, 9798, 9909  
multi-level analysis, 10015  
patterns of disease clustering, 10015  
sheep/*T. evansi*, for study of immuno-pathology, 9824  
transformation, slender to stumpy form, *T. brucei*, 10245  
*T. congolense* parasitaemia patterns in cattle, 10055  
trypanosomiasis  
control, 9783  
human, mouse model, neurological effects, 10078  
tsetse  
control, 9791  
distribution, 10034  
impact of control strategy, 9887  
population dynamics, 9798, 9909, 10150  
response to trapping pressure, 10150  
vegetative change, Ethiopia, 10143

### **monitor lizard**

as host for tsetse  
Central African Republic, 9806  
Kenya, 10041

### **Mozambique**

*G. pallidipes*, gene diversity and gene flow, 10027

**Naganol** *see* suramin

### **Nannomonas**

infecting rhinoceros, 9920  
infecting tsetse, Central African Republic, 9806  
parasite-vector interactions, 9923

### **nets, electric**

in tsetse behaviour studies  
flight, 10031, 10153

### **Niger**

*T. evansi* infection (exp.) in camels  
treatment, 10190

### **Nigeria**

Bauchi State  
*G. m. submorsitans*, 10033  
*G. palpalis*, 10033  
*G. tachinoides*, 10033  
Benue State  
cattle breed productivity, 10067  
Borno State  
trypanosomiasis prevalence  
in goats, 10054  
in sheep, 10054

central  
drug resistant *T. congolense* and *T. vivax* from cattle, 10191  
Jos Plateau  
biting flies, 10052  
*G. p. palpalis*, 10052, 10173  
*G. tachinoides*, 10173  
trypanosomiasis  
in cattle, 9819, 10052, 10173  
in goats, prevalence, 10173  
in sheep, prevalence, 10173  
tsetse status, 10052  
Kaduna State  
*G. m. submorsitans*, 10173  
*G. p. palpalis*, 10173  
*G. tachinoides*, 10173  
trypanosomiasis prevalence  
in cattle, 10173  
in goats, 10173  
in sheep, 10173  
Kano State  
*G. tachinoides*, 10174  
trypanosomiasis prevalence  
in cattle, 10174  
in goats, 10174  
in sheep, 10174  
Lower Benue  
*G. tachinoides*, 10173  
trypanosomiasis prevalence  
in cattle, 10173  
in goats, 10173  
in sheep, 10173  
north-eastern  
trypanosomiasis in cattle, 9934  
northern  
drug resistant *T. congolense* and *T. vivax* from cattle, 10191  
south-eastern  
trypanosomiasis in cattle, prevalence  
in different vegetation zones, 10172  
seasonal, 10172  
trypanosomiasis  
chemotherapy of animal trypanosomiasis, 10191  
in tsetse-free zone, 9933, 10054  
*T. vivax* infection in goats, 9933, 10054  
*T. vivax* infection in sheep, 9933, 10054

#### **nitroimidazoles**

treatment of human trypanosomiasis, 9927  
treatment of *T. b. brucei*-infected mice  
combined with melarsoprol, 9846

#### **non-target organisms**

effect of tsetse control  
on invertebrates, 10018  
aquatic, 10036  
on vertebrates  
birds, 10018  
fish, 10036  
mammals, 10018  
reptiles, 10018

**normalised difference vegetation index (NDVI)**

in tsetse distribution studies, 10154

**odour attractants/baits/stimuli**

acetone, 9799, 9896, 9908, 9910, 9911, 9915, 10031, 10149

butanone, 10156

carbon dioxide, 9908, 9913, 10031

effectiveness studies, 9901

methods for dispensing, 10156

4-methylphenol, 9799, 9911, 10156

octenol, 9799, 9908, 9911, 10031, 10149, 10156

on traps/screens/targets, 9793, 9799, 9901

ox odour, natural, 9799, 9908, 9919, 10031

phenols, 9908, 10031

3-*n*-propylphenol, 9799, 9911, 10156

urine, cow, 9896, 9911, 10149

**odour plumes**

tsetse response to, 9913

wind speed effects, 9913

**ox**

attractiveness for tsetse, 9799, 9908, 9919, 10031

**packed cell volume (PCV)**

in cattle

trypanosome-infected, 9932

trypanotolerant, control of, 10182

in goats

*T. congolense*-infected, 10060, 10183

in sheep

*T. congolense*-infected, 9943

*T. evansi*-infected, 9824

**parasitaemia**

in cattle

profiles in N'Dama cattle, 10055

*T. congolense*-infected

modelling parasitaemia patterns, 10055

trypanotolerant, control of, 10182

in goats

*T. congolense*-infected, 10183

*T. evansi*-infected, 9823

in humans

*T. b. gambiense*-infected, 9810

in sheep

*T. congolense*-infected, 9942

*T. evansi*-infected, 9824

**pentamidine**

cure rate, 9930

dose regimens, 9815

mode of action, 10048

overdose, treatment by charcoal haemo-perfusion, 10050

pharmacokinetics, 9815

treatment of human trypanosomiasis, 9811, 9890, 9898, 9927, 9929, 9930

**pharmacokinetics, 9944**

drug levels in

blood, 10047

CSF, 10047, 10049

plasma, 10047, 10049  
urine, 10047, 10049, 10166

**pigs**

in Cameroon, 9937  
in Côte d'Ivoire, 10144  
reservoir of human trypanosomiasis, 10099  
*T. brucei* infection, 9937  
*T. brucei* stocks from, Uganda, 10206  
*T. congolense* infection, 9937  
*T. simiae* infection, 9937  
*T. vivax* infection, 9937

**plasma**

in pharmacokinetic studies, 10047, 10049  
lipid concentrations, *T. congolense* infection, 9941, 9942  
trace element levels, role in trypanotolerance, 10062

**poultry**

in Côte d'Ivoire, 10144

**quinapyramine**

resistance in *T. congolense*, 10203  
treatment of *T. evansi* infection in camels, 10175

**rabbits in laboratory studies**

*T. brucei* infection  
effect on jejunal segment response to histamine, carbachol and serotonin, 9949  
*T. b. brucei* infection  
effect on acetylcholinesterase level in brain, 9832

**rabbits in laboratory studies (cont.)**

*T. congolense* infection, 10160  
adenosine triphosphatase activity, 9839  
response of adrenal gland, plasma cortisol and glucose, 9948  
thyroid status, 9839  
*T. equiperdum* infection  
auto-antibodies against DNA and collagen, 10077  
*T. evansi* infection  
antibody detection, 10192

**rats in laboratory studies**

as laboratory hosts for tsetse, 9808

*Cricetomys gambianus*

*T. b. gambiense*-infected  
extraction of crude antigens for diagnostic tests, 10072

immunisation with killed *T. evansi*  
haematological changes, 10198

*Mastomys natalensis*

*T. congolense*-infected  
phagocytosis by blood leukocytes, 10080

pancreatic cells, Ca<sup>2+</sup> activity, effect of suramin, 10202

*T. brucei* infection

combination treatment, DFMO and isometamidium, 9967  
effect of protein malnutrition on gossypol antifertility action, 10193  
effect on Ca<sup>2+</sup>-ATPase activity, 10075  
effect on erythrocyte calcium, 10075

*T. b. brucei* infection

sleep disturbance, actimetric analysis, 10076  
sleep-wake cycle, changes, 9952

*T. b. rhodesiense* infection



- trypanocide testing, 9959, 9961, 9962, 9963, 9964
- T. congolense* infection
  - drug effects, 10085
  - trypanocide testing, 9959, 9960, 9961, 9962, 9963
- T. equiperdum* infection
  - trypanocide testing, 9959, 9960, 9962, 9963
- T. evansi* infection
  - immunomodulatory drugs, effect, 9954
  - trypanocide testing, 9959, 9960, 9961, 9962, 9963

#### **remote sensing**

- in tsetse distribution studies, 10034, 10154, 10155

#### **reptiles**

- as hosts for tsetse, Central African Republic, 9806

#### **reservoir hosts**

- domestic animals, Uganda
  - of *rhodesiense* trypanosomiasis, 9972
- potential of cattle
  - in human trypanosomiasis, 9807
- role in epidemiology
  - of human trypanosomiasis, 9784, 10042

#### **rhinoceros, black**

- Nannomonas* infection, 9920
- T. brucei* infection, 9920
- T. congolense* infection, 9920
- T. vivax* infection, 9920

#### **rhinoceros, white**

- translocated
  - risk of spread of human-infective *T. brucei*, 9920
- T. brucei* infection, 9920

#### **RNA**

- T. brucei*
  - editing, 9865, 10231
    - nucleases, 10126
  - g, 9865
    - database, 10129
    - gBP21 binding to, 9993
    - pre-m, chimaeric molecules, secondary structures, 9877
    - requirement for endonucleolytic cleavage of mRNA, 10207
    - three dimensional model, 10226
  - glutamine tRNAs, import into mitochondria, 9992
  - m
    - histone levels, regulation, 9859
    - polysomal procyclin, 9863
    - precursor, 9865
    - procyclin, expression regulation in insect forms, 10219
  - r, pseudouridine residues, mapping, 10123
  - spliced leader RNA gene, transcription, 10114
  - trans* mRNA splicing, 10235
  - U6 snRNA gene promoter, 10238
- trypanosome
  - editing, 9881

#### **rodents in laboratory studies**

- T. brucei* infection, trypanocide testing, 9970
- T. b. gambiense* infection, trypanocide testing, 9970

#### **rural development**

- and tsetse control, 9914

## Rwanda

trypanosomiasis in humans, *rhodesiense*, 9817

## Samorin *see* isometamidium chloride screening

for human trypanosomiasis  
history, 9890  
immunoparasitological, 9784  
in Cameroon, 9810  
mass, 9785, 10043  
parasitological, 9810  
serological, 9810

## screens, 9784

insecticide-treated, 9793  
odour-baited, 9793

## Senegal

*G. p. gambiensis*, 10059

*T. vivax* infection in horses, 10059

## serum

buffalo  
activity of xanthine oxidase, 10196  
camel  
concentrations of micro- and macro-elements in trypanosome-  
infected animals, 10061  
cattle  
foetal bovine, trypanocidal effect, 9955, 10197  
native VSG-specific antibodies, 9840  
trace element levels, role in trypano-tolerance, 10062  
guinea pig  
trypanocidal activity in presence of FBS, 9955, 10197  
human  
DFMO in, 9816  
native VSG-specific antibodies, 9840  
pentamidine concentration, 10050  
trypanocidal factor against *T. evansi*, 9838  
trypanolytic factors, components, 10082  
trypanolytic role of HDL particles, 9841  
mouse  
native VSG-specific antibodies, 9840  
sheep  
pharmacokinetics, 9970

## sheep

Djallonké  
breed status, Côte d'Ivoire, 10144  
*T. congolense* infection (exp.)  
effect on reproductive performance, 10186  
effect on semen quality, 10186  
trypanosome prevalence, Gambia, 9938  
tsetse challenge to, Gambia, 9938  
drug resistance studies, 10191

Finn Dorset

*T. congolense* infection (exp.)

pathophysiology, 9942

plasma lipid concentrations, 9942

Scottish Blackface

*T. congolense* infection (exp.)  
  blood biochemical changes, 9941, 9943  
    influence of dietary protein, 9941  
    influence of dietary roughage, 9943  
  blood haematological changes, 9942  
    influence of dietary roughage, 9943  
  pathophysiology, 9942, 9943  
    effect of diet on, 9943  
  plasma lipid concentrations, 9941, 9942  
serum kinetics of Ir-(COD)-pentamidine tetraphenylborate, 9970  
*T. brucei* infection, Ghana, 9935  
*T. congolense* infection, Ghana, 9935  
*T. congolense* infection (exp.)  
  effect  
    of nutritional level  
      on degree of anaemia, 9942  
    of roughage type, 9943  
    on Leydig cell steroidogenesis, 10185  
      compared to scrotal insulation, 10185  
    on PCV, 9943  
    on plasma lipid concentrations, 9941, 9942  
    on testosterone content, 10185  
  heterophile antibodies to chicken erythrocytes, 9837  
*T. evansi* infection (exp.)  
  effect on body temperature, 9824  
  haematological changes, 9824  
  kinetics, 9824  
  self-cure, 9824  
*T. vivax* infection  
  in Ghana, 9935  
  in Nigeria, 9933, 10054  
trypanosomiasis prevalence, Nigeria, 10174  
trypanotolerance, 9786  
Uda, 9933, 10054  
Yankassa, 9933, 10054  
  *T. brucei* infection, 10173  
  *T. congolense* infection, 10173  
  *T. vivax* infection, 10173

#### **small ruminants**

  trypanotolerance, 9793  
  genetics, 9828

#### **spraying**

  aerial, 9914  
  aerosol application  
    environmental impact, 10036  
ground, using DDT, 9914

**sterile insect technique (SIT)**, 9793, 10036

#### **Stomoxysinae**

*Stomoxys* spp., Nigeria, 10052  
  *S. nigra*, chemoreceptors, 9795

#### **Sudan**

  trypanosomiasis in camels, 10181  
  treatment, 10190

#### **suids**

  as hosts for *G. longipennis*, 9919

#### **suramin**

  effect on rat pancreatic cells, 10202

treatment

- of trypanosomiasis in humans, 9927, 9929
  - combined with DFMO, 9817
  - gambiense*, 9814
  - rhodesiense*, 9811, 9817
  - toxicity, 9814

**survey**

- cluster sample
  - intra-cluster correlation coefficient, 10176
  - community participation potential, 9896, 10139
- entomological, Burkina Faso, 9800, 9922
- epidemiological, Burkina Faso, 9922
- of human trypanosomiasis, Cameroon, 9810
- trypanosomiasis
  - in cattle, Nigeria, 10172
  - in goats, Nigeria, 9933
  - in humans, case-finding
- low participation rate, 10043
  - in sheep, Nigeria, 9933
  - modelling antibody prevalence, 10015

**Tabanidae**

- in Nigeria, 10052, 10174

**Tanzania**

- G. m. centralis*, 9910, 9911, 9912
- G. pallidipes*, 9896, 9910, 9911, 9912
- G. swynnertoni*, 9896, 9910, 9911, 9912
- plants, trypanocidal activity, 9968, 10199, 10200
- trypanosomiasis
  - control, 9790
  - in humans, 9845
- tsetse control, 9790, 9901
- forecasting likelihood of community participation, 9896

**targets**

- as barriers to reinvasion, 9803
- insecticide-treated, 9802, 9914, 9915
  - deltamethrin, 9802
- odour-baited, 9914
- swinger, 9915

**Togo**

- cattle, phenotypic designations, 10065

**transmission**

- cyclical, by *G. pallidipes*, 9795
  - efficiencies from tsetse to cattle
    - of *T. congolense*, 10037
    - of *T. vivax*, 10037
  - human trypanosomiasis, dynamics, Côte d'Ivoire, 10157
  - mechanical, 9819, 10052
    - by *Stomoxys nigra*, 9795
  - parasite-vector interactions, 9923
  - transmissibility and infectivity of drug-resistant *T. congolense*, 10188

**traps/trapping**, 9784, 9789, 9793

- biconical, 9911, 9912, 10033, 10150, 10151
- bipyramidal, 9801
- catch, 9799, 9803
- comparisons, 9801, 10033
- efficiency, 9799, 9801, 10153

- comparison, 9912
- electric, 9912
- Epsilon, 9799, 9912
- F3, 9912, 10033
- for tsetse population sampling, 9911, 9912
- for tsetse population studies
- comparison of Latin square and randomised complete block designs, 10152
- growth regulator treated, 9793
- insecticide-treated, 9793, 9800
  - cypermethrin, 9800
- monoconical screen, 9912
- monopyramidal
  - MP3, 9912
  - MP4, 9912
- monoscreen, 9801
- NG2F, 10149
- NGU, 9912, 10033
- Nitse, 10032, 10033
- odour-baited, 9793, 9799, 9803, 10149, 10150

#### **trypanocides**

- alkyllysophospholipids, 9965
- alkylphosphocholines, 9843, 10088
- alkylpolyamine analogues, 10086
- anionic ruthenium (III) complexes, 9962
- 8-aza-7-deaza-5 $\beta$ -noraristeromycin derivatives, 10094
- bialamicol analogues, 10091
- (+)-7-deaza-5 $\beta$ -noraristeromycin, 10092, 10093
- diospyrin, 9851
- ionic osmium (IV) complexes, 9961
- ionic ruthenium (III) complexes, 9961
- Ir-(COD)-pentamidine tetraphenylborate, 9970
- natural compounds
  - berberine, 9968
  - harmane, 9968
- neutral and octahedral ruthenium (III) complexes, 9964
- neutral iridium (III) complexes, 9960
- neutral osmium (III) and (IV) complexes, 9962
- organometallic and cationic iridium (I) complexes, 9963
- organometallic and cationic rhodium (I) complexes, 9963
- organotin compounds, 10095
- phenothiazines and related polycyclics, 9971
- plants
  - Albizia gummifera*, 9844, 9845
  - Annickia kummeriae*, 10199, 10200
  - Annona senegalensis*, 9844, 9968
  - Asteranthe asterias*, 10199, 10200
  - Bussea occidentalis*, 9844, 9968
  - Cassytha filiformis*, 9958
  - Ehretia amoena*, 9844, 9845, 9849
  - Entada abyssinica*, 9844, 9845
  - Physalis angulata*, 9844, 9968
  - Securinega virosa*, 9844, 9845
  - Vernonia subuligera*, 9844, 9845
- platinum (II) and (IV) complexes, 9959
- purine nucleosides, enhanced, 9974
- screening for activity against

*T. brucei*, 9843, 9965, 9970, 10091, 10092  
*T. b. brucei*, 9851, 9971, 9974, 10086, 10088, 10093, 10094  
*T. b. gambiense*, 9970, 10088  
*T. b. rhodesiense*, 9844, 9845, 9849, 9959, 9961, 9962, 9963, 9964, 9968, 9974, 10086, 10088, 10093, 10094, 10199, 10200  
*T. congolense*, 9959, 9960, 9961, 9962, 9963  
*T. equiperdum*, 9959, 9960, 9962, 9963, 10095  
*T. evansi*, 9959, 9960, 9961, 9962, 9963, 10096  
*T. vivax*, 9958  
screening for cytotoxicity, 9844, 9845, 9847, 9849, 9958, 9960, 9964, 9968, 10087, 10099, 10200  
    triazine derivatives, 10096  
    SIPI-1029, 10096

### **trypanoresistance**

    in livestock, genetics, 10081  
    in mice, genetics, 9951, 10074, 10081, 10195

### **Trypanosoma**

    evolutionary genetics, implications, 9976

### ***T. brucei***

    antigenic variation, 9855, 9978  
        mechanisms, 10211  
        mediation, 9995  
        rate  
            in fly-transmitted infections, 10250  
            in syringe-passaged infections, 10250  
    autoantigen I/6, 10105  
    bloodstream form, 9852, 9857, 9863, 9977, 10097, 10103, 10117, 10118, 10208  
    bloodstream trypomastigotes, 9831  
    Bouaflé group reference stocks, 10180  
    calcium influx, 9874  
    cell cycle, 9859  
    cell signalling, 10002  
    cellulase activity, 10230  
    characterisation of isolates, 10099, 10179, 10180  
    coenzyme A  
        2-enoyl, hydratase activity, 9886  
        -3-hydroxyacyl, dehydrogenase activity  
            NADP<sup>+</sup>-dependent, 9886  
    culture, 9852, 10097  
    developmental regulation, mechanisms, 10229  
    differentiation  
        bloodstream to procyclic form  
            expression of cyclin-1, 10117  
            role of host blood, 9921  
        signalling mechanisms, 10104  
    DNA, 9831  
        β-D-glucosylated, binding of daunorubicin to, 10110  
        kinetoplast  
            electrophoretic comparison, 10137  
    replication, 9880  
        drug effects, 9864  
        drug resistance, 10173, 10204  
        drug targets, 9867, 9871  
        ectophosphatase in procyclics, 10218  
        endocytosis, 9868, 10000  
        endonucleolytic cleavage, gRNA requirement, 10207  
        fructose-1,6-bisphosphate aldolase, 9876, 10127

- α-galactosyl-transferases, 10012
- genetic/s
  - chromosomes
    - large and mini, partitioning, 10108
  - developmental regulation, mechanisms, 10229
  - diversity, 10206
  - endonucleases, 10126
  - expression of toxic gene products, vectors, 10103
  - expression, regulation of, in bloodstream forms, 10243
  - gene disruption, PCR-based, 10220
  - gene sequences, single copy, 10120
  - genes
    - encoding mitochondrial DEAD-box protein, 10237
    - expression, 9857
    - gene-1, expression site-associated, 9857
- T. brucei*** (cont.)
- genetics (cont.)
- genes (cont.)
  - PRP8* homologous, 10235
  - rRNA, analysis, 10098
  - rab*
    - duplication, 10109
    - sequence divergence, 10109
    - Trab 1 and 7, 9990
  - SLA RNA, 10004
  - spliced leader RNA, transcription, 10114
  - U6 snRNA, promoter, 10238
- vsg, expression-site switching, 10116, 10216
- genome
  - mapping and chromosome size polymorphism, 10236
  - segregation, mechanism, 10107
  - sequencing and mapping, 9987
- heterogeneity, 10180
- isoenzymes, 10180
- karyotype nomenclature, 10009
- minisatellite sequence, single locus
  - distinguishing between isolates, 10102
- populations, 10099
- RNA
  - editing, 9865, 10126, 10231
- g
  - database, 10129
  - directed endonuclease, 10126
  - gBP21 binding to, 9993
  - model, 10226
  - pre-m chimaeric molecules, secondary structures, 9877
  - requirement for endonucleolytic cleavage of mRNA, 10207
  - specified uridylate insertion into precursor m, 9865
- glutamine tRNAs, import into mitochondria, 9992
- m
  - polysomal procyclin, 9863
  - precursor, 9865
  - procyclin, 3' untranslated region, expression regulation in insect forms, 10219
  - regulation of histone levels, 9859
- r, pseudouridine residues, mapping, 10123
- trans*-mRNA splicing, 10235

- U6 snRNA gene, promoter, 10238
- telomere/subtelomere duplex, ST-2, 10217
- trans*-splicing, 9996, 10235
- variability, 9784
- glycerol uptake, 10135
- glycolysis, 9977, 9997
- glycolytic enzymes, 9871, 9977
- glycoprotein, flagellum-adhesion, characterisation, 9999
- glycosomal microbodies, targeting by phosphoglycerate kinase, 10003
- glycosomal phosphoglycerate kinase, 9875
- glycosomes, 9886
- glycosylphosphatidylinositol/s (GPI)
  - anchor
    - degrading phospholipases, 10008
    - nature dictated by cell type, 10239
    - octyl *O*- and *S*-glycosides, anchor-related
      - galactosylation, 10012
      - synthesis, 10012
    - role in secretion, 10208
    - structures, 10122
  - biosynthesis, 9989
  - host cell regulation, 9956
  - myristoylation, 10134
  - signal transduction in macrophages, 10130
  - structure, 9989
- growth
  - control, TNF- $\alpha$  involvement, 10121
  - rate and carbon regimen, promastigotes, 10233
- hypoxanthine-guanine phosphoribosyl-transferase, 10132
- identification, 10179, 10180
- infecting cattle, 9800, 9932, 9935, 10053
  - Friesian, 10172
  - Muturu, 10172, 10173
  - N'Dama, 10172, 10173
  - Zebu, 10172, 10173
- infecting dogs, 9826
- infecting domestic animals, 9972, 10179
- infecting man, 9972
- infecting mice, 9833, 9946
- infecting pigs, 9937
- infecting rabbits, 9949
- infecting rats, 9836, 9967, 10075, 10193
- infecting rhinoceros, 9920
- infecting rodents, 9970
- infecting sheep, 9935, 10173
- infectivity, 10040
- insect forms, 10219
- intoxication with ricin, 9879
- in vitro* studies, 9836
- karyotype nomenclature, 10009
- lipids, methylation, 10223, 10224
- $\alpha$ -mannosyltransferases, acceptors for, 10212
- mating, intraclonal, 10111
- metabolic compartmentation, 9858
- microtubules
  - flagellar, 10005



- organising centres and  $\gamma$ -tubulin, 10007
- subpellicular, 10005
- mitochondria
  - endonucleases, 10126
  - enzymatic editing complex from, 10242
- import of glutamine tRNAs, 9992
- `multicoloured coats', 10249
- NADH fumarate reductase inhibition, 9884
- nuclear calcium flux, 10011
- ornithine decarboxylase
  - pyridoxal 5'-phosphate binding, role of Arg-277, 10124
- out-crossing, and mating, 10111
- paraflagellar rod, 9853
- pentose phosphate pathway, 10101
- peptide library screening, 9875, 9876, 10127
- 6-phosphogluconate dehydrogenase, 9864
- phosphoglycerate kinase
  - activation, 9979
  - internal region, targeting to glycosomal microbodies, 10003
- phosphoribosyltransferase, 10132
- pleomorphic, 9852, 9863
- polyamine metabolism, 9988
- procyclic form, 9831, 9861, 9886, 10103, 10117, 10208, 10218, 10247
- procyclin, 10241, 10243
- profilin homologue, identification, 10136
- promastigotes, 10233
- proteasome, 20S, 10131
- protein/s
  - cellular, methylation, 10223, 10224
  - cytoskeletal
    - autoantigen I/6, 10105
  - G-strand binding, 10217
  - hydrogenosomal
    - targeting sequence function, 10225
  - isoprenylation, 9861
  - kinases, 9981
    - KFR1, IFN- $\gamma$  activation, 10118
  - mitochondrial
    - DEAD-box, 10237
    - gBP21, binding to gRNA, 9993
    - targeting sequence function, 10225
  - nucleic acid binding, 10253
  - phosphorylation, 9981
  - prenylation, 10252
  - procyclic acidic repetitive, 10247
  - ribosomal L18, cloning and sequencing, 9985
  - surface, conserved structural motifs, 9856
  - synthesis, inhibition, 9863
- protein kinase C, 10130
- protein tyrosine kinases, 10130
- proteinases, 9984
- purines, acquisition, 10215
- pyridoxal kinase, 10244
- ribonuclease H, molecular cloning and expression, 10115
- ribonucleotide reductase, R1 and R2 subunits, 10227
- RIME/ingi retroposons, heterogeneous transcripts, 9885

secretion, 10000  
 sterol metabolism, chemotherapeutic potential, 9982  
 survival in tsetse, expression of specific procyclin forms, 10241  
 transferrin receptor, 9868  
 transformation  
   bloodstream to procyclic form, role of host blood, 9921  
   long slender to short stumpy, model, 10245  
 trypanocide testing, 9843, 9965, 9970, 10091, 10092  
 T-tubulin, 10006  
 $\gamma$ -tubulin  
   localisation to microtubule organising centres, 10007  
   molecular characterisation, 10007  
 ultrastructure, changes after storage, 9878  
 virulence, 10040  
 VSG  
   expression of bloodstream VSGs in procyclics, 10208  
   expression of *T. b. gambiense* in procyclics, 10239  
   expression site promoter  
     binding of *trans*-acting factors to, 10240  
   expression sites, 9980, 9995  
     lacking 70bp repeat sequences, 9995  
     221, GPI anchor structure, 10122  
   zymodemes, 10180  
***T. brucei* ssp.**  
 DNA content, wide variation, 10119  
 genetic crosses  
   heritability of human infectivity, 10222  
 infecting cattle, 10053  
 infecting humans, 9831  
 infecting tsetse, 9806  
***T. brucei* spp.**  
 genetic diversity, 10206  
 infecting cattle, 10206  
 infecting dogs, 10206  
 infecting humans, characterisation, 10099, 10206  
 infecting pigs, characterisation, 10099, 10206  
 infecting tsetse, 10206  
***T. brucei brucei***  
 ABC transporters, 9869  
 S-adenosylmethionine transporter, 10112  
 alternative oxidase, cloning, sequencing and functional activity, 9983  
***T. brucei brucei* (cont.)**  
 antibodies, antipeptide, against trypanopain-Tb, 10248  
 bloodstream form, 9854, 9870  
   respiration and growth, inhibition by ascofuranone, 9998  
 culture, 9975  
 distinguished from *T. b. rhodesiense*, 9807  
 kDNA minicircles, inheritance in genetic crosses, 10221  
 drug effects, 9846, 9850, 9969, 10090  
 genome research, and evolution, 9986  
 hypoxanthine uptake, procyclics, 10232  
 infecting cattle, 9807, 10170, 10182  
 infecting mice, 9834, 9835, 9846, 9850, 9953, 9968, 10078, 10079, 10084, 10088, 10090  
 infecting rabbits, 9832  
 infecting rats, 9952, 10076

*in vitro* studies

growth inhibition, 9870  
respiratory inhibition, 9870

NADH dehydrogenase, rotenone-sensitive, 9854

nucleoside hydrolases, inhibitors, 10125

phosphohydrolases, Golgi-associated, 10113

procyclic form, 9854, 10213, 10232

proteasome, 20S, 10234

protein isoprenylation, 9860

self-regulation of population in tsetse, 10161

serum activity against, 10196

slender form, 10245

strain 427, 'GPEET' procyclin in procyclic culture forms, 10213

stumpy form, 10245

transformation, long slender to short stumpy, model, 10245

trypanocide testing, 9851, 9971, 9974, 10086, 10088, 10093, 10094

***T. brucei gambiense***

antigens, crude, extraction, 10072

characterisation of isolates, 10180

culture, 9975

GPI anchor, nature dictated by cell type, 10239

'Group I', 10099

identification, 10180

infecting humans, 9785, 9810, 9813, 9814, 9816, 9924, 10045,  
10046, 10162, 10167

infecting mice, 10088, 10201

infecting rodents, 9970

infecting wild mammals, 10180

isoenzymes, 10180

resistance to human HDL, mechanism, 9991

serum activity against, 9955, 10197

slender form, 10245

stumpy form, 10245

transformation, long slender to short stumpy, model, 10245

trypanocide testing, 9970, 10088

VSG, expression in procyclic *T. brucei*, 10239

***T. brucei rhodesiense***

S-adenosylmethionine transporter, 10112

bloodstream form, 9849

clonality, 9807

distinguished from *T. b. brucei*, 9807

kDNA minicircles, inheritance in genetic crosses, 10221

drug effects, 9866

drug resistance, 9929, 9972

gene for T lymphocyte triggering factor, 10251

genetic exchange, 9807

genetic makeup, 9807

genome, survey, 10106

infecting domestic animals, 9972

infecting humans, 9807, 9811, 9817, 9972, 10042, 10166

infecting mice, 9947, 10088, 10201

infecting rats, 9959, 9961, 9962, 9963, 9964

kinetoplastid membrane protein-11, 9882

ornithine decarboxylase, 9866

population genetics, 9807

resistance to human HDL, mechanism, 9991

transformation, long slender to short stumpy, model, 10245

trypanocide testing, 9844, 9845, 9849, 9959, 9961, 9962, 9963, 9964, 9968, 9974, 10086, 10088, 10093, 10094, 10199, 10200

***T. congolense***

acid phosphatase activity, 9883

antigenic variation, 9827, 9855

bloodstream form, 9883

characterisation, 10179, 10180

Con A, 9821

culture, axenic, effect of cytokines on growth, 10094

cysteine protease, comparison, 10214

drug effects, 10085

drug resistance, 9802, 10069, 10071, 10173, 10188, 10191, 10203

drug resistant isolates, chromosome profiles, 10071

drug sensitivity, 10191

EATRO 325, 9805

epimastigote form, 9808

attachment, 10210

genetic heterogeneity, 10180

hsp70/BiP, 9821

identification, 10179, 10180

IL 1180

resistance to isometamidium, 10203

sensitivity to isometamidium, 10069

IL 13E3, 10056, 10057

IL 3338, infectivity and transmissibility in *G. m. centralis*, 10188

IL 3343, resistance to isometamidium, 10069

infecting cattle, 9800, 9802, 9825, 9827, 9932, 9935, 10037, 10052, 10053, 10070, 10191

Boran, 9821, 9830, 10056, 10057, 10069, 10188

Friesian, 10172

Gobra, 9936

Muturu, 10172

N'Dama, 9821, 9936, 10172, 10173

N'Dama  $\exists$  Gobra, 9936

White Fulani, 9934

Zebu, 10172, 10173

infecting dogs, 9826, 9827

infecting domestic animals, 10179

infecting domestic ruminants, 9940

infecting donkeys, 9800

infecting goats

Kigezi, 10060

Mashona, 10068

Mubende, 10060

Red Sokoto, 10173

Small East African, 10060, 10183

West African Dwarf, 10173

infecting livestock, 10081

infecting mice, 9809, 9951, 10081, 10083, 10203

infecting pigs, 9937

infecting rabbits, 9839, 9948

infecting rats, 9808, 9959, 9960, 9961, 9962, 9963, 10080, 10085

infecting rhinoceros, 9920

infecting sheep, 9837, 9935, 10185

Djallonké, 10186

Finn Dorset, 9942

Scottish Blackface, 9941, 9942, 9943

Yankassa, 10173  
infecting tsetse, 9805, 9808, 9809, 10160, 10181  
infecting wild mammals, 10180  
Kilifi type, 10180  
life cycle, 9808  
long form, 9805  
mesocyclic form, 9808  
metacyclic form, 9805, 9808  
procyclic form, 9808  
proteinases, 9984  
riverine-forest type, 10160, 10179, 10180  
gRNA database, 10129  
rRNA genes, analysis, 10098  
savanna type, 9805, 9809, 10160, 10179, 10180  
transmission efficiency from tsetse to cattle, 10037  
trypanocide testing, 9959, 9960, 9961, 9962, 9963  
ultrastructure, changes after storage, 9878  
VSG, 9821, 10133  
ZRE/G143/90, 9808

***T. cruzi***

cysteine protease, comparison, 10214  
flagellum-adhesion glycoprotein, homologue in *T. b. brucei*, 9999  
genome research, and evolution, 9986  
NADH fumarate reductase inhibition, 9884  
trypanocide testing, 9851

***T. equinum***

ultrastructure, changes after storage, 9878

***T. equiperdum***

antigenic variation, 9855  
infecting horses, 10168  
infecting rabbits, 10077  
infecting rats, 9959, 9960, 9962, 9963  
gRNA, database, 10129  
trypanocide testing, 9959, 9960, 9962, 9963, 10095

***T. evansi***

antigen, soluble, electrophoretic study, 10254  
antigenic variation, 9855  
bloodstream form, 10097  
cryopreserved, viability and infectivity, 10128  
culture, 10097  
kDNA, electrophoretic comparison, 10137  
effect of human serum, 9838  
immunisation of rats, 10198  
infecting camels, 10175, 10177, 10178, 10181, 10184, 10187, 10190  
infecting cattle, 10096  
infecting goats, 9823  
infecting mice, 9950, 10096  
infecting rabbits, 10192  
infecting rats, 9954, 9959, 9960, 9961, 9962, 9963  
infecting sheep, 9824  
TREGU 2143, 9824  
trypanocide testing, 9959, 9960, 9961, 9962, 9963, 10096  
ultrastructure, changes after storage, 9878

***T. grayi***

infecting tsetse, 9806

***T. simiae***

infecting pigs, 9937

infecting tsetse, 9922  
rRNA genes, analysis, 10098

***T. vivax***

antigenic variation, 9855  
culture, 9975  
diagnostic antigen, 10073  
drug resistance, 9819, 10173, 10191  
drug sensitivity, 9819, 10191

***T. vivax*** (cont.)

infecting cattle, 9800, 9825, 9932, 9935, 10051, 10052, 10173,  
10174, 10191  
Boran, 9822  
Friesian, 9819, 10172  
Muturu, 10172  
N'Dama, 10172, 10173  
Zebu, 10172, 10173  
infecting domestic animals, 10179  
infecting goats, 9819, 9933, 9935, 10054, 10169  
Red Sokoto, 10173  
West African Dwarf, 9820, 10058, 10173  
infecting horses, 10059  
infecting livestock, 10081  
infecting mice, 9958, 10081  
infecting pigs, 9937  
infecting rhinoceros, 9920  
infecting sheep, 9933, 9935, 10054  
Yankassa, 10173  
infecting tsetse, 9922, 10052, 10073  
KETRI 2501, 9822  
rRNA genes, analysis, 10098  
transmission efficiency from tsetse to cattle, 10037  
trypanocide testing, 9958  
VSG, small, 9862

**trypanosome/s**

S-adenosylmethionine metabolism, inhibition, 9848  
antigenic variation, 10209  
and vaccines, 10001  
bloodstream form, 9840  
drug resistance, 9793  
drug resistance mechanisms, 9973  
use of field isolates, 9973  
establishment in tsetse midgut, 9923  
glyceraldehyde-3-phosphate dehydrogenase  
synthesis of inhibitors, 10100  
human infective, identification, 9945  
infecting camels, 10061  
infecting cattle, 9938, 10171  
infecting donkeys, 9938  
infecting goats, 9938  
infecting horses, 9938  
infecting sheep, 9938  
infecting tsetse, 9784  
infection rates in tsetse, 10158  
interaction with tsetse vector, 9923  
maturation in tsetse midgut, 9923  
phylogeny, 10098  
programmed cell death, 10010

research, history, 9902  
RNA editing, 9881  
surface coat, 9840  
transmission efficiency, 10037

trypanothione reductase  
  change from glutathione reductase, 10246  
  inhibitors, virtual screening, 10228  
  substrate specificity, 9994  
VSGs, 9840

### **trypanosomiasis, general**

association with glomerulopathy, 9842  
biology, 9893  
cluster sample surveys  
  intra-cluster correlation coefficient, 10176  
constraint to livestock production, 10141  
control, 9893  
  in Cameroon, 9897  
  in Central African Republic, 9888  
  in Chad, 9889  
  in Congo, 9898  
  in Equatorial Guinea, 9899  
  in Gabon, 9891  
  in Tanzania, 9790  
strategies, 9914  
  effectiveness, 9914  
  sustainability, 9914  
diagnostics, 9794  
economic assessment, 9894  
evaluation as constraint to land-use, 9894  
historical aspects, 9893  
public health status, 9895  
review, 10016  
socio-economic impact, 9894  
threat to human health, 10141  
treatment, 9794  
valuation of human welfare effects, 9894

### **trypanosomiasis in animals**

clinical symptoms/pathological effects  
  abortion, 9939  
  anaemia, 9824, 9939, 9942, 9943, 10056, 10058, 10059, 10183  
  depression, 10059  
  dyspnoea, 9823  
  emaciation, 10059  
  endocrinological disturbances, 9940  
    hypothalamic-pituitary axis, 9940  
  enlarged liver, 9823  
  enlarged lymph nodes, 9823  
  enlarged spleen, 9823  
  fever, 9939, 10058, 10059  
  haematological changes, 10056, 10057  
  hormonal imbalance, 9940, 10185  
  hypoalbuminaemia, 9941, 9942  
  immunosuppression, 10187  
  lethargy, 9823  
  leukocytosis, 9824  
  leukopenia, 10056

- low birth weight, 9822
- lymphocytosis, 9824
- muscle wastage, 9823
- oedema, 9823, 10059
- premature birth, 9822
- pyrexia, 9823
- reduced fertility, 9939
- reduced libido, 10186
- reproductive disorder, 9940
- semen abnormalities, 10186
- still birth, 9939
- thrombocytopenia, 9942, 10056
- weight loss, 9939, 10060
- control, 9800
- diagnosis, 9925, 9926, 10051
- pathogenesis, role of nutrition, 9941, 9943, 10183
- prevalence, 9791
- treatment, 9791
- trypanosomiasis in camels**
  - diagnosis, 10177, 10178, 10181, 10184
  - enzymes, 10181
  - haematology, 10181
  - in Kenya, 10175, 10190
  - in Sudan, 10181, 10190
  - pathology, 10181, 10184
  - serum biochemistry, 10061, 10181
  - treatment, 10184, 10190
  - T. evansi* infection, 10175, 10177, 10178, 10184, 10187
- trypanosomiasis in cattle**
  - control, 9788, 9800
  - diagnosis, 9936, 10170, 10171
  - immunosuppression, 9825
  - in Burkina Faso, 9800
  - in Ethiopia, 9802, 9932
  - in Ghana, 9935
  - in Nigeria, 9819, 9934, 10052, 10173, 10174
  - in sub-Saharan Africa, 9788
  - in Uganda, 10171
  - in Zambia, 10053
  - incidence
    - in Kenya, 10150
    - in Nigeria, 9934
  - prevalence
    - in Ethiopia, 9802, 9932
    - in Gambia, 9938
    - in Ghana, 9935
    - in Nigeria, 10052, 10172, 10174
  - risk
    - in Ethiopia, 9932
    - in Nigeria, 10172
  - survey, 10172
  - treatment, 9802, 9819
  - T. brucei* infection, 9800, 9932, 9935, 10053, 10182
  - T. congolense* infection, 9800, 9802, 9932, 9935, 9936, 10052, 10053, 10069, 10172, 10173
  - T. vivax* infection, 9800, 9819, 9932, 9935, 10051, 10052, 10172, 10173, 10174



**trypanosomiasis in domestic ruminants**

effects on reproduction, 9940

*T. congolense* infection, 9940

**trypanosomiasis in goats**

effect on health and productivity, 9939

prevalence

in Gambia, 9938

in Ghana, 9935

in Nigeria, 9933, 10054, 10173, 10174

in Uganda, 10060

in Zambia, seasonal, 9939

protective immunity, 9939

susceptibility, effect of age, 9939

*T. congolense* infection, 10060, 10068, 10173, 10183

*T. vivax* infection, 9933, 9935, 10054, 10058, 10169, 10173, 10174

**trypanosomiasis in horses**

diagnosis, 10168

in Senegal, 10059

prevalence

in Ethiopia, 10168

in Gambia, 9938

treatment, 10059

*T. equiperdum* infection, 10168

*T. vivax* infection, 10059

**trypanosomiasis in humans**

clinical symptoms/pathological effects, 9787, 10165

asthenia, 10044

cervical lymphadenopathy, 9817

CNS invasion, 9927

demyelination, 9927

encephalopathy, 9785, 9814

fever, 10044

hypergammaglobulinaemia, 10044

intracranial haemorrhage, 9812

local inflammatory reaction, 9927

meningitis, 9812

meningoencephalitis, 10165

neurological disorders, 10044

psychical disorders, 10044

sedimentation rate, increase, 10044

somnolence, 10044, 10165

weight loss, 10044

control, 9783, 9784, 9785, 9793

CSF status, 9930, 10044

detection, 9783, 9810, 9831, 10014

diagnosis, 9785, 9810, 9811, 9812, 9831, 9924, 9925, 9926, 10044, 10162

distribution, 9787

endotoxin antibodies, 10045

epidemics, 9807

epidemiology, 9785, 9787, 10165

etiology, 9787

fear of drug-induced mortality, 10043

foci, 9807, 9810

**trypanosomiasis in humans (cont.)**

historical aspects, 9785, 9787, 9888, 9889, 9890, 9891, 9897, 9898, 9899, 9900, 10016

immune response, 9927, 10016, 10164  
immunology, 9787, 10046  
immunopathogenesis, 10046  
immunopathology, 10016  
in Cameroon, 9810, 9897, 9924  
in Central Africa, 9783  
in Central African Republic, 9888  
in Chad, 9889  
in children, 10044, 10167  
in Congo, 9784, 9898  
in Côte d'Ivoire, 9784, 9831  
in East Africa, 9807  
in Equatorial Guinea, 9899  
in French Equatorial Africa, 9890  
in Gabon, 9891, 10044  
in Kenya, 9811, 10042  
in Rwanda, 9817  
in Tanzania, 9845  
in Uganda, 9784, 9807, 9845, 9849, 9918  
in Zaire, 9785, 9812, 10043, 10162  
in Zambia, 9807  
incidence, 9787  
    in Zaire, 9785, 10142  
modelling, 10014  
    neurological effects, in mice, 10078  
pathology, and immunological status, 9928  
    physiopathology, 9928  
prevalence, Zaire, 9785  
    public health impact, 10016  
    public health status, 9895  
    reservoir, 9785, 9807  
    screening, 9784, 9785, 9810, 10043  
    socio-economic impact, 10016  
    surveillance, 10163  
    transmission dynamics  
        role of human behaviour, 10157  
transmission, Lambwe Valley, Kenya, 10042  
treatment, 9783, 9784, 9785, 9793, 9818, 9844, 9845, 9849, 9929,  
    9930, 9931, 9968, 10014  
    combination therapy, 10166  
    DFMO, 9816, 9817, 9929, 10044, 10162, 10167  
    melarsoprol, 9811, 9813, 9814, 9816, 9927, 9929, 10024, 10046  
    nifurtimox, 9929  
    nitroimidazole derivatives, 9927  
    pentamidine, 9811, 9927, 9929, 9930  
    relapse, 9929, 9930, 10167  
    suramin, 9811, 9814, 9817, 9927, 9929  
*T. b. gambiense* infection, 9785, 9810, 9813, 9814, 9816, 9930, 10046,  
    10162, 10167  
*T. b. rhodesiense* infection, 9807, 9811, 9817, 10042, 10166  
**trypanosomiasis in livestock**  
incidence, West Africa, effect on distribution, 9786  
    risk, Ethiopia, 9932  
**trypanosomiasis in pigs**  
diagnosis, 9937  
*T. brucei* infection, 9937  
*T. congolense* infection, 9937

*T. simiae* infection, 9937

*T. vivax* infection, 9937

**trypanosomiasis in sheep**

prevalence

in Gambia, 9938

in Ghana, 9935

in Nigeria, 9933, 10054, 10173, 10174

*T. brucei* infection, 9935, 10173

*T. congolense* infection, 9935, 9941, 9942, 9943, 10173, 10185, 10186

*T. vivax* infection, 9933, 9935, 10054, 10173, 10174

**trypanosusceptibility**

genetic mapping, 10063

in cattle

Boran, 9821

Galana Boran, 9822

N'Dama  $\exists$  Boran

genetic mapping, 10063

phenotype and microsatellite allele frequency data, 10065

Zebu, 9786

in goats

Kigezi, 10060

Mubende, 10060

Small East African, 10060

**trypanotolerance**

anaemia, control, 10182

genetic/s

imprinted genes, identification, 10074

mapping, 10063

markers, 9828

selection, marker assisted, 9828

haemolytic complement, control, 10182

in animals, 9784

in cattle, 9786, 9793

Borgou, 10182

bovine analogues of human trypanolytic factors, 10066

Keteku, 10062

Lagune, 10182

N'Dama, 9821

N'Dama  $\exists$  Boran

genetic mapping, 10063

Orma Boran, 9821

phenotype and microsatellite allele frequency data, 10065

in goats, 9786

in humans, 9784

in mice, 10074, 10083

in sheep, 9786

Djallonké, 10186

in small ruminants, 9793, 9828

parasitaemia, control, 10182

phenotypic marker, anaemia, 10063

role of trace elements in maintenance, 10062

trypanolytic antibodies, 10182

**trypanotolerant**

cattle, 10141

in Nigeria, 10067

**Trypanozoon**

drug resistance/sensitivity, 10173

- infecting cattle, 10206
- infecting dogs, 10206
- infecting humans, 10206
- infecting pigs, 10206
- infecting tsetse, 10206
- infectivity to humans, potential, 10173
- parasite-vector interactions, 9923

**tryparsamide, 10016**  
mode of action, 10048

## **Uganda**

Busoga

*T. brucei* isolates from, 10206

Mukono County

trypanosomiasis in cattle

diagnosis, 10171

plants, trypanocidal activity, 9968

south-eastern

Buvuma Islands

reservoir of parasite diversity, 10206

*T. brucei* isolates, characterisation, 10206

trypanosomiasis risk, 10206

*T. brucei* stocks from man and domestic animals, drug sensitivity testing, 9972

*T. b. rhodesiense* epidemics, 9918

*T. congolense* infection (exp.) in goats, 10060, 10183

trypanosomiasis in humans, 9845, 9849

*rhodesiense*, 9807

Tororo focus, 9807

tsetse trapping campaign, 9784

## **variant antigen type (VAT)**

LiTat 1.3, *T. b. gambiense*, 9924

## **variant surface glycoprotein (VSG)**

*T. brucei*

expression of bloodstream VSGs in procyclics, 10208

expression site promoter, binding of *trans*-acting factors to, 10240

expression sites, 9980, 9995

gene, expression site switching, 10116

GPI anchor, nature dictated by cell type, 10239

221, GPI anchor structure, 10122

*T. b. gambiense*

expression in procyclic *T. brucei*, 10239

GPI anchor, nature dictated by cell type, 10239

*T. congolense*, 9821, 10133

*T. vivax*, small, characterisation, 9862

trypanosome, 9840

## **Zaire (Democratic Republic of Congo)**

plants, trypanocidal activity, 9968

trypanosome infections in tsetse, 10158

trypanosomiasis in humans, 9812, 10043, 10162

case-finding surveys, participation rate, 10043

control, 9785

epidemiology, 9785

*gambiense*, 9785  
history, 9785  
plight of 'patients within borders', 10142  
screening, 10043

### **Zambia**

Eastern Province

trypanosomiasis in cattle

*T. brucei* infection, 10053

*T. congolense* infection, 10053

*G. m. morsitans*, 10038

cattle as host for, 10038

trypanosome infections in tsetse, 10158

trypanosomiasis in goats, 9939

effect on health and productivity, 9939

trypanosomiasis in humans, *rhodesiense*, 9807

### **Zimbabwe**

*G. pallidipes*, gene diversity and gene flow, 10027

odour attractants for tsetse, methods for dispensing, trial, 10156

tsetse behaviour studies, 9908

host location, 9908

tsetse challenge to cattle, 9829

tsetse control

comparison of costs, 9914

DDT, 9804, 9914

deltamethrin, 9804